Women diagnosed with breast cancer who want to freeze their eggs and embryos before tumor treatment leads to infertility can do this without delaying the start of chemotherapy, a U.S. study suggests.
Researchers focused on 89 women newly diagnosed with breast cancer who received counseling at a fertility clinic about a relatively new technique known as random-start ovarian stimulation. This process doesn’t wait for a woman’s natural menstrual cycle to stimulate the ovaries to release eggs and can be done in about two weeks, compared with four to six weeks with older ovarian stimulation techniques timed to coincide with menstruation.
Overall, 67 of the women proceeded with random-start ovarian stimulation before beginning cancer treatment.
With fertility treatment, women started chemotherapy an average of 38 days after their breast cancer diagnosis, compared with 39 days when patients decided against fertility preservation.
“What this tells us is these women can still go on to build a family,” said senior study author Dr. Mitchell Rosen, a reproductive health researcher at the University of California San Francisco.
“It only takes two weeks, and it isn’t going to cause any delay in their cancer treatment,” Rosen said in a telephone interview.
When chemotherapy is needed soon after a breast cancer diagnosis, doctors generally advise that it begin within four to six weeks to avoid hurting women’s survival odds.
Chemotherapy can cause infertility by damaging the ovaries and by triggering an early menopause in women of childbearing age.
For the study, researchers examined data from medical records for breast cancer patients between the ages of 18 and 45 who were referred to the UCSF Center for Reproductive Health between 2011 and 2017 before starting chemotherapy.
Women started chemotherapy at roughly the same time whether or not they decided to first harvest eggs and freeze eggs or embryos, researchers report in Human Reproduction.
One limitation of the study is that it didn’t look at other reasons beyond fertility preservation that might influence how long it takes for women to start chemotherapy, such as tests to pinpoint the type of tumors imaging to find out how far cancer has spread or patients making arrangements to take time off of work or prepare their lives for chemo.
The study also wasn’t a controlled experiment designed to prove how fertility preservation directly influences the time it takes to start chemotherapy, and the results from one fertility center might not represent what all women would experience.
Even so, the findings suggest that random-start ovarian stimulation may be a viable option for women with breast cancer or other types of malignancies who don’t want to lose their ability to have children after tumors are in remission, said Dr. Kutluk Oktay, director of the Innovation Institute for Fertility Preservation and IVF in New York and a researcher at Yale University School of Medicine in New Haven, Connecticut.
“With this approach, a patient can be started on ovarian stimulation even on the day of the initial consultation and can be done with embryo or egg freezing in two weeks,” Oktay, who wasn’t involved in the study, said by email.
“And if she has more time, she can even do multiple cycles of freezing without risking a delay in chemotherapy,” Oktay said. “Random start extends all women who are considering embryo or egg freezing before chemotherapy for any type of cancer more flexibility and ability to preserve fertility with the least delay before initiating ovary damaging cancer treatments.”
Whether you or a loved one is searching for hair loss solutions, lymphedema chronic swelling solutions, or mastectomy solutions, Ricky Knowles Hair and Wellness is here to help you rediscover confidence. A husband and wife team with over 40 years of combined specialized training, we offer our clients exclusive access to the latest advances in mastectomy, hair loss and lymphedema products and services.
Showing posts with label cancer treatment. Show all posts
Showing posts with label cancer treatment. Show all posts
Thursday, September 21, 2017
Wednesday, September 6, 2017
How one app is helping to tighten the link between cancer patients and their doctors
When chemotherapy patient Allison Hailey meets with Dr. Angela Kueck at Texas Oncology in Austin, she comes prepared.
That is because Hailey's phone displays graphs, charts and logs of her medications, mood changes and physical health — courtesy of an app called ChemoWave.
Since its launch on June 29, ChemoWave is giving chemotherapy patients and their doctors more insight on treatment plans, side effects and mental health. The app arrives on the scene at a time when health care is becoming a major focus for tech giants like Amazon and Apple, and joins an increasingly crowded field of biometric tech that helps people track vital health information.
ChemoWave is designed to help track a wide variety of vital data like symptoms, exercise, water intake and medications. It then compiles those figures into a health compliance database, then graphs the information so patients — and their doctors — can connect what symptoms are related to what medication or activity. Patients can also send daily updates to their doctors, which can be critical when treating cancer. A recent study by the Journal of the American Medicine Association found a 21 percent increase in survival time for patients who tracked and reported their symptoms. Thirty-one percent were more likely to report better quality of life and physical functions, the study said. "I have a better understanding as opposed to when I see [Hailey] every couple weeks in the office with her trying to remember what side effects she had on what day," Kueck told CNBC. "You can see trends over time, so we can plan for her next cycle" of chemo, she added. "It improved communication and we're connected more."
Matt Lashey, the developer of the app and co-founder of Treatment Technologies & Insights, came up with ChemoWave when his partner Richard Grenell was diagnosed with cancer in 2013. Each morning, Lashey would administer Grenell a survey about how he was feeling emotionally and physically, along with any side effects. Lashey's background in data analysis propelled him to do some correlation analysis from the surveys to track Grenell's symptoms. "I started doing some simple correlation analysis to see what things were related to his highs and lows, and our doctor loved (the charts)," the former research consultant for Discovery Communications and Nationwide Insurance told CNBC. "We could point to very specific days when something had occurred, and having those graphs and data really led to a lot more efficient collaboration with him." ChemoWave features an added benefit, according to Kueck: helping to improve communication between patient and doctor. "I might see a patient every three weeks, and when trying to recount what happened on day two or four, it's hard for them to remember so it does take a lot of time of the visit," Kueck said. Using the app, she now gets daily updates.
Kueck said there haven't been any widely used apps among her patients, and ChemoWave is fulfilling a large need among those involved in chemotherapy. "I'm already in the loop. We can just talk about today and the future. It's definitely streamlined the visits in the office," she said. ChemoWave is free to download, in order to get it as widely disseminated as possible, according to Lashey. He's also meeting with care organizations, doctors and pharmaceutical companies to explore future partnerships and possible financing. "There could be a lot of money to be made if we were to charge money for this app, but we decided that the real value is in the data," Lashey said. "The hope is that getting it into the hands of patients will start to add value to their life on an immediate basis, and that if we can stick with this and we can get the app with funding that we need, there's going to be money to be made in the future," he added. Grenell is now healthy and sees his doctor regularly, while Hailey said she plans on using the app throughout her treatment. "It does exactly what it's supposed to do, and it provides even more information for a patient to have some control over what what's going on with us," she said.
ChemoWave is designed to help track a wide variety of vital data like symptoms, exercise, water intake and medications. It then compiles those figures into a health compliance database, then graphs the information so patients — and their doctors — can connect what symptoms are related to what medication or activity. Patients can also send daily updates to their doctors, which can be critical when treating cancer. A recent study by the Journal of the American Medicine Association found a 21 percent increase in survival time for patients who tracked and reported their symptoms. Thirty-one percent were more likely to report better quality of life and physical functions, the study said. "I have a better understanding as opposed to when I see [Hailey] every couple weeks in the office with her trying to remember what side effects she had on what day," Kueck told CNBC. "You can see trends over time, so we can plan for her next cycle" of chemo, she added. "It improved communication and we're connected more."
Matt Lashey, the developer of the app and co-founder of Treatment Technologies & Insights, came up with ChemoWave when his partner Richard Grenell was diagnosed with cancer in 2013. Each morning, Lashey would administer Grenell a survey about how he was feeling emotionally and physically, along with any side effects. Lashey's background in data analysis propelled him to do some correlation analysis from the surveys to track Grenell's symptoms. "I started doing some simple correlation analysis to see what things were related to his highs and lows, and our doctor loved (the charts)," the former research consultant for Discovery Communications and Nationwide Insurance told CNBC. "We could point to very specific days when something had occurred, and having those graphs and data really led to a lot more efficient collaboration with him." ChemoWave features an added benefit, according to Kueck: helping to improve communication between patient and doctor. "I might see a patient every three weeks, and when trying to recount what happened on day two or four, it's hard for them to remember so it does take a lot of time of the visit," Kueck said. Using the app, she now gets daily updates.
Kueck said there haven't been any widely used apps among her patients, and ChemoWave is fulfilling a large need among those involved in chemotherapy. "I'm already in the loop. We can just talk about today and the future. It's definitely streamlined the visits in the office," she said. ChemoWave is free to download, in order to get it as widely disseminated as possible, according to Lashey. He's also meeting with care organizations, doctors and pharmaceutical companies to explore future partnerships and possible financing. "There could be a lot of money to be made if we were to charge money for this app, but we decided that the real value is in the data," Lashey said. "The hope is that getting it into the hands of patients will start to add value to their life on an immediate basis, and that if we can stick with this and we can get the app with funding that we need, there's going to be money to be made in the future," he added. Grenell is now healthy and sees his doctor regularly, while Hailey said she plans on using the app throughout her treatment. "It does exactly what it's supposed to do, and it provides even more information for a patient to have some control over what what's going on with us," she said.
Monday, July 31, 2017
Socialization with Cancer Survivors Matters During Chemotherapy
A new study published by Network Science suggests that social interaction may be crucial for the success of chemotherapy in patients with cancer. The authors found that patients were more likely to achieve 5-year survival if they interacted with other patients during chemotherapy who also survived for 5 or more years.
On the other hand, patients had a slightly increased risk of mortality if they interacted with patients who died in less than 5 years, according to the study. “People model behavior based on what’s around them,” said lead author Jeff Lienert. “For example, you will often eat more when you’re dining with friends, even if you can’t see what they’re eating. When you’re bicycling, you will often perform better when you’re cycling with others, regardless of their performance.” The authors aimed to determine how social interaction affects patients undergoing chemotherapy.
On the other hand, patients had a slightly increased risk of mortality if they interacted with patients who died in less than 5 years, according to the study. “People model behavior based on what’s around them,” said lead author Jeff Lienert. “For example, you will often eat more when you’re dining with friends, even if you can’t see what they’re eating. When you’re bicycling, you will often perform better when you’re cycling with others, regardless of their performance.” The authors aimed to determine how social interaction affects patients undergoing chemotherapy.
Friday, July 21, 2017
Is it safe to exercise when having chemotherapy?
Chemotherapy can be notoriously difficult, not only emotionally but mentally and physically as well. Being diagnosed with cancer can come as a real blow to patients and their families. However, while rest and recuperation is needed, don't feel that you need to give up your former active lifestyle. Engaging in regular exercise can improve your strength and help your body build up its defenses against further infection.
People with certain types of cancer or having particular treatments may need to avoid some types of exercise and there are some situations where you need to take extra care. For example, people with stomach or other digestive system cancers or cancer that has spread to the bone should not do heavy weight training. If movement causes pain, rapid heart rate, and an increased shortness of breath avoiding or reducing physical activity is advised. However, exercise is not only safe and possible during cancer treatment, but it can improve how well you function physically and your quality of life, with some studies showing that it can help speed up recovery after treatment. Mr Jonathan Krell, consultant oncologist at Leaders in Oncology Care and one of London Medical Concierge's network of doctors gives advice on how best to stay active when going through chemotherapy.
1. Exercise can help Partaking in regular exercise increases muscle strength, joint flexibility, and general conditioning, all of which may be impaired by surgery and some therapies. Exercise is known to improve cardiovascular function and elevates your mood, offering a drug-free relief for feelings of depression when going through chemotherapy. Exercise also helps to control weight, and gaining weight during and after treatment can increase the risk of the cancer reoccurring.
2. Finding your own level is important Too much exercise can make you tired but so can too little. Therefore, finding your own level is important but you shouldn't push too hard. Research shows that exercise can help with the side effects of cancer treatment such as pain, tiredness and sickness and can also improve your mood, reduce anxiety and improve quality of life. More importantly, research into some cancers such as breast cancer shows that exercise and a healthy lifestyle can help reduce the risk of a person's cancer coming back after potentially curative treatment.
3. Build up gradually "If you are having treatment or have recently finished, it is fine to start exercising if you feel like it. How much you do really depends on how fit you are generally. If you've never done much exercise, you'll have to build up your level gradually. If you do too much one day, you may feel very tired and sore the next day. Something important to remember is that you don't need to feel that you always have to do more exercise than yesterday; little and often is more effective than lengthy workouts every day and some days you will have more energy than others.
4. Enjoy it "Each patient's exercise programme should be based on what is safe, effective and enjoyable. You should take into account the type of cancer you have, your cancer treatment, your stamina, strength and fitness level. What may seem like a small amount of exercise for a healthy person may be a lot for someone going through cancer.
6. Try half an hour "Try to do about 30 minutes of physical activity throughout the day, this can include walking, gardening and other general household chores, such as vacuuming, do these regular activities at a higher level of intensity in order for your fitness level to improve.
7. Mix it up As your fitness improves you'll be able to up the level of exercise and activities you do. You could try long walks, cycling, yoga or light gym work. Listen to your body and work at your own pace, and if you experience sickness, dizziness or pain stop exercising immediately. If your treatment is making you feel especially tired, try exercising for a shorter amount of time and at a lower intensity, or leave exercising until the following day instead.
8. But listen to your body Your fitness and energy levels will fluctuate throughout the different stages of your treatment cycle. For example, immediately after treatment you are likely to feel tired and unwell and it's advisable to stick to light exercising or leaving it until the next day. Studies have shown that exercising can improve your energy levels and help you feel less tired, but listen to your body, don't put pressure on yourself to exercise and do what you feel comfortable with."
People with certain types of cancer or having particular treatments may need to avoid some types of exercise and there are some situations where you need to take extra care. For example, people with stomach or other digestive system cancers or cancer that has spread to the bone should not do heavy weight training. If movement causes pain, rapid heart rate, and an increased shortness of breath avoiding or reducing physical activity is advised. However, exercise is not only safe and possible during cancer treatment, but it can improve how well you function physically and your quality of life, with some studies showing that it can help speed up recovery after treatment. Mr Jonathan Krell, consultant oncologist at Leaders in Oncology Care and one of London Medical Concierge's network of doctors gives advice on how best to stay active when going through chemotherapy.
1. Exercise can help Partaking in regular exercise increases muscle strength, joint flexibility, and general conditioning, all of which may be impaired by surgery and some therapies. Exercise is known to improve cardiovascular function and elevates your mood, offering a drug-free relief for feelings of depression when going through chemotherapy. Exercise also helps to control weight, and gaining weight during and after treatment can increase the risk of the cancer reoccurring.
2. Finding your own level is important Too much exercise can make you tired but so can too little. Therefore, finding your own level is important but you shouldn't push too hard. Research shows that exercise can help with the side effects of cancer treatment such as pain, tiredness and sickness and can also improve your mood, reduce anxiety and improve quality of life. More importantly, research into some cancers such as breast cancer shows that exercise and a healthy lifestyle can help reduce the risk of a person's cancer coming back after potentially curative treatment.
3. Build up gradually "If you are having treatment or have recently finished, it is fine to start exercising if you feel like it. How much you do really depends on how fit you are generally. If you've never done much exercise, you'll have to build up your level gradually. If you do too much one day, you may feel very tired and sore the next day. Something important to remember is that you don't need to feel that you always have to do more exercise than yesterday; little and often is more effective than lengthy workouts every day and some days you will have more energy than others.
4. Enjoy it "Each patient's exercise programme should be based on what is safe, effective and enjoyable. You should take into account the type of cancer you have, your cancer treatment, your stamina, strength and fitness level. What may seem like a small amount of exercise for a healthy person may be a lot for someone going through cancer.
6. Try half an hour "Try to do about 30 minutes of physical activity throughout the day, this can include walking, gardening and other general household chores, such as vacuuming, do these regular activities at a higher level of intensity in order for your fitness level to improve.
7. Mix it up As your fitness improves you'll be able to up the level of exercise and activities you do. You could try long walks, cycling, yoga or light gym work. Listen to your body and work at your own pace, and if you experience sickness, dizziness or pain stop exercising immediately. If your treatment is making you feel especially tired, try exercising for a shorter amount of time and at a lower intensity, or leave exercising until the following day instead.
8. But listen to your body Your fitness and energy levels will fluctuate throughout the different stages of your treatment cycle. For example, immediately after treatment you are likely to feel tired and unwell and it's advisable to stick to light exercising or leaving it until the next day. Studies have shown that exercising can improve your energy levels and help you feel less tired, but listen to your body, don't put pressure on yourself to exercise and do what you feel comfortable with."
Wednesday, July 5, 2017
Woman develops cancer treatment that offers hope to ailing dogs
Millions of cats and dogs get diagnosed with cancer each year, and a new treatment is helping to change their prognosis.
The revolutionary veterinary cancer treatment is called VetiVax and it uses the animals tumor cells to create a personalized treatment to help fight the disease.
The treatment helps trigger the immune system of the pet to help it recognize the tumor as foreign. It's being used to help dogs, cats and horses combat cancer.
The company behind the treatment, Torigen Pharmaceuticals, was founded by UConn alumna Ashley Kalinauskas four years ago. "This is my passion, this is my drive," she said. "Were changing how pets are treated and this is a modality that can be considered when a pet is diagnosed with cancer." Kalinauskas said her graduate professor at Notre Dame, Mark Suckow began research on tissue vaccines in 2004. When his dog Sadie was diagnosed with cancer in 2010, she said he came up with this method to try and fight the disease. "She had tumors growing almost all over her body and the veterinarian's prognosis was take her home, enjoy her over Christmas and right after the holidays we're gonna have to put her down," Kalinauskas said.
"He took a portion of Sadie's tumor, created it into the personalized treatment, gave it back over a series of three weeks and he noticed the tumors started to recede." In two and a half years, Kalinauskas said 150 animals have been treated with VetiVax. "We have unproven safety and unproven efficacy at the moment; however, what we do know is the animals have a favorable outcome after being diagnosed," she said.
One of those animals is a Yorkshire Terrier named Chloe whose owner Linda Levy told FOX61 since she's been given the treatment, she's had no signs of cancer. "Unfortunately, we all know that the terrible thing of having a dog is that you know you're going to see them go before you," Levy said. "You just want them to have the best possible life and treatment if they get sick and I feel like I've been able to find that for her." Kalinauskas works at a dedicated laboratory space in Farmington through the UConn Technology Incubation Program.
Her team members are also located in Minnesota and Arkansas. The company works with veterinarians to treat animals around the country. The cost of VetiVax is $1200. VetiVax can work for solid tumors including Melanoma, Squamous Cell Carcinoma, Fibrosarcoma, Soft Tissue Sarcoma, Hemangiosarcoma, Hepatocellular Carcinoma, Nasal Carcinoma, Osteosarcoma, Mast Cell Tumors, Basal Cell Carcinoma and Transitional Cell Carcinoma. "It's our belief that 10 years from now us as humans will start as our first line of defense with immunotherapies followed by the heavy hitters if it doesn't work with chemotherapy and radiation," she said.
Thursday, June 29, 2017
New treatment for advanced breast cancer: Ribociclib
This year, 253,000 women will be diagnosed this year with invasive breast cancer, and for women battling advanced forms of the disease, there’s now a new treatment. Doctors are calling it a first line of defense for advanced breast cancer.
With a hot pink ride, decked out with lighted wheels, nothing is going to get in the way of mother Sally McGiffin and her daughter Shannon McGiffin.
Not even cancer. “When we first got diagnosis we sat and cried maybe half an hour to an hour, and then she looked at me and said this disease is not going to beat me,” Sally told Ivanhoe.
That attitude and a newly-approved FDA drug called Ribociclib, has kept Shannon McGiffin’s stage four metastic breast cancer under control. “It’s a miracle. It really is a miracle for me to be able to have survived this long.” Shannon said. Oncologist Heather Han, MD, of the Moffitt Cancer Center in Tampa, Florida says when combined with hormonal therapy, Ribociclib stops signals that cancer cells use to grow and divide. “I’m obviously very excited that this drug finally actually quickly got approved, and I’m able to be there to help patients to do better,” Dr. Han explained.
Doctor Han says the Ribociclib combination can be used as the first line of defense. The risk of progression or death has been reduced by 44 percent. Dr. Han continued, “So it’s been in clinical trial for several years, but FDA was able to approve it quickly when it showed dramatic improvement of the patients.” The side effects for her have been high blood sugar levels and fatigue. “I do spend a lot of my time sleeping,” Shannon admitted. For Shannon, it’s not a cure, but it has given her precious time with those who matter most. Candidates for this drug usually can be patients with newly diagnosed advanced breast cancer, hormone receptor positive and HER2 negative. Patients’ EKGs must be monitored in the first few weeks of taking the drug to make sure it doesn’t cause any cardiac issues.
Not even cancer. “When we first got diagnosis we sat and cried maybe half an hour to an hour, and then she looked at me and said this disease is not going to beat me,” Sally told Ivanhoe.
That attitude and a newly-approved FDA drug called Ribociclib, has kept Shannon McGiffin’s stage four metastic breast cancer under control. “It’s a miracle. It really is a miracle for me to be able to have survived this long.” Shannon said. Oncologist Heather Han, MD, of the Moffitt Cancer Center in Tampa, Florida says when combined with hormonal therapy, Ribociclib stops signals that cancer cells use to grow and divide. “I’m obviously very excited that this drug finally actually quickly got approved, and I’m able to be there to help patients to do better,” Dr. Han explained.
Doctor Han says the Ribociclib combination can be used as the first line of defense. The risk of progression or death has been reduced by 44 percent. Dr. Han continued, “So it’s been in clinical trial for several years, but FDA was able to approve it quickly when it showed dramatic improvement of the patients.” The side effects for her have been high blood sugar levels and fatigue. “I do spend a lot of my time sleeping,” Shannon admitted. For Shannon, it’s not a cure, but it has given her precious time with those who matter most. Candidates for this drug usually can be patients with newly diagnosed advanced breast cancer, hormone receptor positive and HER2 negative. Patients’ EKGs must be monitored in the first few weeks of taking the drug to make sure it doesn’t cause any cardiac issues.
Labels:
breast cancer,
cancer breakthrough,
cancer treatment
Location:
Houston, TX, USA
Wednesday, June 7, 2017
9 prostate cancer myths, debunked
After skin cancer, prostate cancer is the most common type of cancer in men. In 2017, the American Cancer Society estimates about 161,360 new cases of prostate cancer will be diagnosed and about 26,730 men will die from it.
The good news is that survival rates for prostate cancer are high, but experts say there are several myths out there about how it’s diagnosed and treated, and how it may affect men’s health and sex lives.
1. It’s an old man’s disease. According to the American Cancer Society, six in 10 cases of prostate cancer are diagnosed in men ages 65 and older. Although many men think prostate cancer is something they need to start thinking about in their 60s, men as young as 40 are diagnosed with prostate cancer too. What’s more, screening all men between ages 45 and 49 for prostate cancer can predict almost half of all deaths several decades later, a 2013 study in the journal BMJ found.
2. There are no symptoms. It’s true that many men with prostate cancer may not have any symptoms, even for those who have metastatic disease. Many symptoms of prostate cancer can also mimic other benign conditions like prostatic hyperplasia (BPH) or an enlarged prostate, a urinary tract infection (UTI) or another type of cancer. Nevertheless, if you notice urinary frequency, urgency, a slow or weak flow or an obstruction of the flow, blood in your urine or ejaculate, bone pain, or unexpected weight loss, you should see your doctor to be evaluated, Dr. Chung-Han Lee, a medical oncologist at Memorial Sloan Kettering Westchester in West Harrison, New York, told Fox News.
3. Blood PSA levels are only one way to make a diagnosis. High blood prostate-specific antigen (PSA) levels usually indicate prostate cancer, but the only definitive way to diagnose it is with a prostate biopsy, Lee said.
4. You must start treatment right away. If you’re diagnosed with prostate cancer, your doctor will first determine the stage and your risk group — low, intermediate or high-risk — before deciding on a treatment plan. He’ll also take into account other conditions you may have, like obesity, heart disease and type 2 diabetes, as well as your smoking history, before deciding on the course of treatment. If you have other medical problems but a low-grade prostate cancer, for example, your doctor may hold off on treatment. Yet if you’re otherwise healthy and have an aggressive form of prostate cancer, treatment may be done earlier.
5. Natural remedies can help. Selenium, alkaline water, high-dose vitamin C, and even a combination of maple syrup and baking soda have been cited as ways to prevent and treat prostate cancer. The thinking behind them is, “If you alkalize your blood then cancer has a hard time surviving because cancer cells love an acidic environment,” Dr. Geo Espinosa, a naturopathic and functional medicine doctor in New York City, and author of, “Thrive, Don’t Only Survive,” told Fox News. Yet experts agree there’s no evidence any of these can help.
6. Surgery will end your sex life. Surgery will likely cause impotence at least initially, but most men will regain the ability to become erect with treatments such as Kegel exercises. How the surgery will impact your sex life depends on whether or not your doctor has to remove the nerve bundles that run on either side of the prostate. “If they can save at least one of them, then they can still have erections, sometimes with assistance,” Lee said. Medications like Viagra or injections, or a a penile implant or pump can help.
7. Diet and lifestyle don’t matter. You might think there’s no way to reduce your risk for prostate cancer, but diet and lifestyle actually play a significant role. Diets low in carbohydrates and sugar like the Mediterranean diet, and moderate to vigorous exercise three to four hours a week have been shown to help prevent the disease. It’s also a good idea to get 15 to 30 minutes of sun exposure sans sunscreen on 40 percent of your body, or talk to your doctor about a supplement, as low levels of vitamin D may predict aggressive prostate cancer, a 2016 study out of Northwestern Medicine found. Also, herbs like curcumin and boswellia lower inflammation and reduce biological markers that contribute to cancer, Espinosa said.
8. Treatment is a cure. Within 10 years of prostate cancer treatment, 40 percent of the time PSA levels will start to rise again, Espinosa said. It’s also not uncommon to be diagnosed and treated for low-grade prostate cancer and years later be diagnosed again with metastatic prostate cancer. If you’ve have prostate cancer, it’s important to be monitored roughly every three to six months within the first one to two years of treatment, After two years, you should get checked out every six to 12 months. If the PSA is undetectable after five years, you should be monitored every 12 months.
9. It’s fatal. The risk that prostate cancer will be fatal depends on how aggressive it is and the other medical conditions you may have. The good news is that for all stages of prostate cancer, the survival rates are high: The five-year survival rate is nearly 100 percent; the 10-year survival rate is 98 percent; and the 15-year survival rate is 95 percent.
1. It’s an old man’s disease. According to the American Cancer Society, six in 10 cases of prostate cancer are diagnosed in men ages 65 and older. Although many men think prostate cancer is something they need to start thinking about in their 60s, men as young as 40 are diagnosed with prostate cancer too. What’s more, screening all men between ages 45 and 49 for prostate cancer can predict almost half of all deaths several decades later, a 2013 study in the journal BMJ found.
2. There are no symptoms. It’s true that many men with prostate cancer may not have any symptoms, even for those who have metastatic disease. Many symptoms of prostate cancer can also mimic other benign conditions like prostatic hyperplasia (BPH) or an enlarged prostate, a urinary tract infection (UTI) or another type of cancer. Nevertheless, if you notice urinary frequency, urgency, a slow or weak flow or an obstruction of the flow, blood in your urine or ejaculate, bone pain, or unexpected weight loss, you should see your doctor to be evaluated, Dr. Chung-Han Lee, a medical oncologist at Memorial Sloan Kettering Westchester in West Harrison, New York, told Fox News.
3. Blood PSA levels are only one way to make a diagnosis. High blood prostate-specific antigen (PSA) levels usually indicate prostate cancer, but the only definitive way to diagnose it is with a prostate biopsy, Lee said.
4. You must start treatment right away. If you’re diagnosed with prostate cancer, your doctor will first determine the stage and your risk group — low, intermediate or high-risk — before deciding on a treatment plan. He’ll also take into account other conditions you may have, like obesity, heart disease and type 2 diabetes, as well as your smoking history, before deciding on the course of treatment. If you have other medical problems but a low-grade prostate cancer, for example, your doctor may hold off on treatment. Yet if you’re otherwise healthy and have an aggressive form of prostate cancer, treatment may be done earlier.
5. Natural remedies can help. Selenium, alkaline water, high-dose vitamin C, and even a combination of maple syrup and baking soda have been cited as ways to prevent and treat prostate cancer. The thinking behind them is, “If you alkalize your blood then cancer has a hard time surviving because cancer cells love an acidic environment,” Dr. Geo Espinosa, a naturopathic and functional medicine doctor in New York City, and author of, “Thrive, Don’t Only Survive,” told Fox News. Yet experts agree there’s no evidence any of these can help.
6. Surgery will end your sex life. Surgery will likely cause impotence at least initially, but most men will regain the ability to become erect with treatments such as Kegel exercises. How the surgery will impact your sex life depends on whether or not your doctor has to remove the nerve bundles that run on either side of the prostate. “If they can save at least one of them, then they can still have erections, sometimes with assistance,” Lee said. Medications like Viagra or injections, or a a penile implant or pump can help.
7. Diet and lifestyle don’t matter. You might think there’s no way to reduce your risk for prostate cancer, but diet and lifestyle actually play a significant role. Diets low in carbohydrates and sugar like the Mediterranean diet, and moderate to vigorous exercise three to four hours a week have been shown to help prevent the disease. It’s also a good idea to get 15 to 30 minutes of sun exposure sans sunscreen on 40 percent of your body, or talk to your doctor about a supplement, as low levels of vitamin D may predict aggressive prostate cancer, a 2016 study out of Northwestern Medicine found. Also, herbs like curcumin and boswellia lower inflammation and reduce biological markers that contribute to cancer, Espinosa said.
8. Treatment is a cure. Within 10 years of prostate cancer treatment, 40 percent of the time PSA levels will start to rise again, Espinosa said. It’s also not uncommon to be diagnosed and treated for low-grade prostate cancer and years later be diagnosed again with metastatic prostate cancer. If you’ve have prostate cancer, it’s important to be monitored roughly every three to six months within the first one to two years of treatment, After two years, you should get checked out every six to 12 months. If the PSA is undetectable after five years, you should be monitored every 12 months.
9. It’s fatal. The risk that prostate cancer will be fatal depends on how aggressive it is and the other medical conditions you may have. The good news is that for all stages of prostate cancer, the survival rates are high: The five-year survival rate is nearly 100 percent; the 10-year survival rate is 98 percent; and the 15-year survival rate is 95 percent.
Thursday, May 18, 2017
Hospital Heroes: Knitters make thousands of hats for chemo patients
Dr. Edda Fields-Black worked at Carnegie Mellon University until she was diagnosed with breast cancer.
“As it is for many women, it was quite a surprise,” she told Fox News.
Fields-Black has since taken a leave of absence to battle her illness, which she said has also been a tough journey for her two kids.
"One is a teenager one is in elementary school, and so they have their own takes on mom being sick,” she said. But there’s a silver lining, she said, at Magee-Womens Hospital where she’s getting treatment. Back in 2014, the hospital started taking volunteer knitters who made hats for patients. "We had originally made baby hats and we have switched to chemo caps because unfortunately there’s a great need for them,” Dena Chottiner, founder of the volunteer knitters, said.
Those involved believe the hats are important because of the need it serves. "I think the changes in body image with breast cancer—they’re really significant. You know, it’s hard, it’s hard," Fields-Black said of her treatment. Chottiner said the knitters have volunteered more than 1,000 hours since the initiative first started.
Organizers equated this to more than 3,000 hats made for patients at the hospital. Their efforts haven't gone unnoticed by the patients. “Just the outpouring of love and support that I’ve gotten from so many people--people I know, people I don’t know or didn’t know, people I’ve never met, like the knitters [is welcoming]", Fields-Black told Fox News. And for those who hesitate to take a hat, Chottiner said she knows exactly how to entice them.
“I’d I say ‘You have to take a hat. I have to keep these ladies off the street and out of trouble,’” she joked. And the knitters don’t plan to stop anytime soon, Chottiner said. "I’m just so happy that people, you know, use them, wear them, like them, comment on them, and that’s all part of it,” Chottiner said.
"One is a teenager one is in elementary school, and so they have their own takes on mom being sick,” she said. But there’s a silver lining, she said, at Magee-Womens Hospital where she’s getting treatment. Back in 2014, the hospital started taking volunteer knitters who made hats for patients. "We had originally made baby hats and we have switched to chemo caps because unfortunately there’s a great need for them,” Dena Chottiner, founder of the volunteer knitters, said.
Those involved believe the hats are important because of the need it serves. "I think the changes in body image with breast cancer—they’re really significant. You know, it’s hard, it’s hard," Fields-Black said of her treatment. Chottiner said the knitters have volunteered more than 1,000 hours since the initiative first started.
Organizers equated this to more than 3,000 hats made for patients at the hospital. Their efforts haven't gone unnoticed by the patients. “Just the outpouring of love and support that I’ve gotten from so many people--people I know, people I don’t know or didn’t know, people I’ve never met, like the knitters [is welcoming]", Fields-Black told Fox News. And for those who hesitate to take a hat, Chottiner said she knows exactly how to entice them.
“I’d I say ‘You have to take a hat. I have to keep these ladies off the street and out of trouble,’” she joked. And the knitters don’t plan to stop anytime soon, Chottiner said. "I’m just so happy that people, you know, use them, wear them, like them, comment on them, and that’s all part of it,” Chottiner said.
Tuesday, May 9, 2017
How assembling the right cancer team may save your life
Moments after Eve Bender was told that a suspicious spot on her breast was cancerous, she phoned her brother, Lew Bender, who runs a cancer research company. “He said, ‘Don’t worry about it, it’s like an in-grown toenail, you just fix it,’” the sales executive recalls.
His blithe response helped Bender sleep that night, but by 7 a.m. the next morning, she was back on the phone. Her doctor friend, Hara Schwartz, advised her not to be emotional, to get a couple of opinions and treat it.
She then called four breast-cancer survivors in her network, and battered them with questions: Where do I start? Who’s the best surgeon? What’s the timeline for surgery? In quick succession, the native New Yorker had assembled her “cancer team”: two top cancer doctors, one at Columbia University Medical Center (CUMC), the hospital that diagnosed her, and another at Memorial Sloan Kettering for a second opinion; her boyfriend, Derek Bensen, for emotional support; Amy Cole, a close friend who would attend some appointments with her; Eileen Z. Fuentes, a patient navigator at CUMC; her boss, Jane Seo, who offered her immediate support at work; and, for post-surgery, Luana DeAngelis, a holistic practitioner who helps during treatment and recovery through her You Can Thrive! organization in Manhattan. “I realized that I couldn’t do this alone,” says Bender, 55. “The way to win is to be the quarterback of your own team.”
People diagnosed with cancer often choose to keep a low profile — they don’t want pity, they want their privacy and for their lives to operate “business as usual.” But by creating a team — experts, friends, patient advocates, wellness practitioners and therapy group members — the road to recovery can be less bumpy, and even transformative. “Our job as doctors is to prevent sickness, but it’s not just about getting through the operation and radiation and chemotherapy,” says Sheldon M. Feldman, director of breast cancer services at Montefiore Medical Center. “It’s about offering complete care so a patient can live a long, healthy, normal life for decades to come.” He believes that “having a healing team should be a standard part of any cancer patient’s health plan.” Fuentes, from Bender’s team, knows the value of this firsthand.
At age 34, the patient advocate — a service offered at most cancer centers — was diagnosed with Stage 2 breast cancer. Now cancer-free for nearly two years, she feels a special connection to her patients, and says having a strong caregiving team is as important as having a good clinical one. “[Patients] talk more openly to me than to their doctors,” says the integrative cancer care and wellness coach. “I’ll listen to their story and then my job is to say, ‘Bring your daughter, bring your friend, bring a notebook and write down these questions.’” Fuentes helps figure out the people patients need on their teams, and does everything from assigning tasks to scheduling appointments with different doctors on the same day. She’ll even arrange free hotel rooms if needed. “I tell my patients, ‘When all of this gets too confusing, I’ll be there.’” Clinical social worker Tammy Rosenthal, diagnosed with Stage 3 cancer at age 72, assembled a “virtual team.” With local support groups, says the Millington, NJ, resident, she ran “the risk of bumping into my patients.” Instead, she sent a mass e-mail to friends and family, and added the ones with generous responses to an e-mail chain. Within weeks, Rosenthal had around 50 people with whom she kept in touch. Ten people on her team were cancer survivors, including one who “had the same surgeon, the same oncologist, the same radiologist — and she was two years ahead of me, so she would help walk me through her experience without overdramatizing it or making it sound too small,” says Rosenthal, who now shows no evidence of the disease.
Her chemo and radiation teammate was her husband, Dave, and she eventually joined a Livestrong group at the YMCA in Basking Ridge, plus got into spinning and Zumba with eight others in the group. Two years on, Rosenthal is chasing after her 6-month-old grandson and is loving her new pixie cut. “My hairdresser rooted for me all along, too,” she says. “We were making lemonade out of lemons.” Brooklyn-based psychologist Paulette Sherman, 46, also kicked cancer with the help of a team. “I wanted a plan for success so I could keep working and seeing my clients, be there for my two kids and handle a 90-minute train commute to the hospital,” she says, five years after her diagnosis. “I actually had 34 people on my healing team playing different roles.” Her high-school friend (also a doctor) gave Sherman medical advice; a neighbor provided nutritional guidance; and a “cancer friend” whom she met at a cancer yoga class traded tips and tricks for coping with her. In addition, she says, “My spiritual teacher Christopher Dilts, a counselor and ‘angel intuitive’ who is based in California, spoke with me weekly and offered ways to remain centered,” Sherman says. Her “wellness practitioners” also included family: Husband Ian took her on weekly date nights during the course of her chemotherapy; her dad gave her car-service and massage vouchers; and her mother-in-law baby-sat whenever necessary.
Without her cancer team, Sherman says, “I would have gotten through the experience, but it might have felt like a nightmare instead of a healing spiritual journey.” Batya Reckson, an oncology social worker at Mount Sinai, says the spiritual component is crucial. “Everything happens so quickly that often patients don’t prioritize their mental health,” she says. That’s why she always works closely with patients — especially those who seem isolated, such as new immigrants or non-English speakers — to find people in their lives or their community to help them feel cared for. Treating cancer, Reckson says, intrinsically takes a village. “A hospital team, a network of friends and family, and community resources should always be a part of the cure.” Bender is grateful that she had a network of friends, family and even friends of friends to guide her. But even if you don’t have family, says the cancer survivor, “you can reach out to other people with your disease. Trust me: They will stop their lives and help you.”
She then called four breast-cancer survivors in her network, and battered them with questions: Where do I start? Who’s the best surgeon? What’s the timeline for surgery? In quick succession, the native New Yorker had assembled her “cancer team”: two top cancer doctors, one at Columbia University Medical Center (CUMC), the hospital that diagnosed her, and another at Memorial Sloan Kettering for a second opinion; her boyfriend, Derek Bensen, for emotional support; Amy Cole, a close friend who would attend some appointments with her; Eileen Z. Fuentes, a patient navigator at CUMC; her boss, Jane Seo, who offered her immediate support at work; and, for post-surgery, Luana DeAngelis, a holistic practitioner who helps during treatment and recovery through her You Can Thrive! organization in Manhattan. “I realized that I couldn’t do this alone,” says Bender, 55. “The way to win is to be the quarterback of your own team.”
People diagnosed with cancer often choose to keep a low profile — they don’t want pity, they want their privacy and for their lives to operate “business as usual.” But by creating a team — experts, friends, patient advocates, wellness practitioners and therapy group members — the road to recovery can be less bumpy, and even transformative. “Our job as doctors is to prevent sickness, but it’s not just about getting through the operation and radiation and chemotherapy,” says Sheldon M. Feldman, director of breast cancer services at Montefiore Medical Center. “It’s about offering complete care so a patient can live a long, healthy, normal life for decades to come.” He believes that “having a healing team should be a standard part of any cancer patient’s health plan.” Fuentes, from Bender’s team, knows the value of this firsthand.
At age 34, the patient advocate — a service offered at most cancer centers — was diagnosed with Stage 2 breast cancer. Now cancer-free for nearly two years, she feels a special connection to her patients, and says having a strong caregiving team is as important as having a good clinical one. “[Patients] talk more openly to me than to their doctors,” says the integrative cancer care and wellness coach. “I’ll listen to their story and then my job is to say, ‘Bring your daughter, bring your friend, bring a notebook and write down these questions.’” Fuentes helps figure out the people patients need on their teams, and does everything from assigning tasks to scheduling appointments with different doctors on the same day. She’ll even arrange free hotel rooms if needed. “I tell my patients, ‘When all of this gets too confusing, I’ll be there.’” Clinical social worker Tammy Rosenthal, diagnosed with Stage 3 cancer at age 72, assembled a “virtual team.” With local support groups, says the Millington, NJ, resident, she ran “the risk of bumping into my patients.” Instead, she sent a mass e-mail to friends and family, and added the ones with generous responses to an e-mail chain. Within weeks, Rosenthal had around 50 people with whom she kept in touch. Ten people on her team were cancer survivors, including one who “had the same surgeon, the same oncologist, the same radiologist — and she was two years ahead of me, so she would help walk me through her experience without overdramatizing it or making it sound too small,” says Rosenthal, who now shows no evidence of the disease.
Her chemo and radiation teammate was her husband, Dave, and she eventually joined a Livestrong group at the YMCA in Basking Ridge, plus got into spinning and Zumba with eight others in the group. Two years on, Rosenthal is chasing after her 6-month-old grandson and is loving her new pixie cut. “My hairdresser rooted for me all along, too,” she says. “We were making lemonade out of lemons.” Brooklyn-based psychologist Paulette Sherman, 46, also kicked cancer with the help of a team. “I wanted a plan for success so I could keep working and seeing my clients, be there for my two kids and handle a 90-minute train commute to the hospital,” she says, five years after her diagnosis. “I actually had 34 people on my healing team playing different roles.” Her high-school friend (also a doctor) gave Sherman medical advice; a neighbor provided nutritional guidance; and a “cancer friend” whom she met at a cancer yoga class traded tips and tricks for coping with her. In addition, she says, “My spiritual teacher Christopher Dilts, a counselor and ‘angel intuitive’ who is based in California, spoke with me weekly and offered ways to remain centered,” Sherman says. Her “wellness practitioners” also included family: Husband Ian took her on weekly date nights during the course of her chemotherapy; her dad gave her car-service and massage vouchers; and her mother-in-law baby-sat whenever necessary.
Without her cancer team, Sherman says, “I would have gotten through the experience, but it might have felt like a nightmare instead of a healing spiritual journey.” Batya Reckson, an oncology social worker at Mount Sinai, says the spiritual component is crucial. “Everything happens so quickly that often patients don’t prioritize their mental health,” she says. That’s why she always works closely with patients — especially those who seem isolated, such as new immigrants or non-English speakers — to find people in their lives or their community to help them feel cared for. Treating cancer, Reckson says, intrinsically takes a village. “A hospital team, a network of friends and family, and community resources should always be a part of the cure.” Bender is grateful that she had a network of friends, family and even friends of friends to guide her. But even if you don’t have family, says the cancer survivor, “you can reach out to other people with your disease. Trust me: They will stop their lives and help you.”
Tuesday, April 25, 2017
FDA Warns of 14 ‘Fraudulent’ Cancer Cure Companies
The claims seem remarkable. "If a person eats 6-12 apricot kernels per day, they will never have to worry about cancer," one site says. "Silymarin also seems to have anticancer properties. It can stop cancer cells from multiplying, kill cancer cells, and block their blood supply," says another.
They're also false, the Food and Drug Administration says. It's warned 14 companies to stop making claims about herbal products and other treatments marketed to treat or prevent cancer.
They cannot and some may be dangerous, the FDA says.
"These companies used slick ads, videos, and other sophisticated marketing techniques, including testimonials about miraculous outcomes," the FDA's Donald Ashley and Douglas Stearn wrote in a blog post. "Often a single product was promoted as a treatment or cure for multiple diseases in humans and animals." The FDA has listed the 14 companies on its website and detailed the false claims they have made about their products, which include herbs, tinctures, supplements, teas and salves. The claims range from curing cancer to "detoxifying" the liver. t's illegal to make such claims without proving they are true and going through the FDA's process for verifying them. Just putting a little disclaimer at the bottom of an ad saying the FDA has not verified the claims doesn't cut it, the agency said.
"Hoping to skirt the law on a technicality, some sellers made false claims and then in small print provided a disclaimer that their products are not intended to diagnose, treat, cure or prevent any disease," Ashley and Stearn wrote. "Making such obvious claims and then saying later that you are not doing so might seem clever, but the technique does not comply with federal laws intended to protect public health." The companies are taking advantage of frightened cancer patients and their loved ones, said consumer safety officer Nicole Kornspan. And they make a lot of money doing it. Americans spend $30 billion a year on alternative therapies.
"Anyone who suffers from cancer, or knows someone who does, understands the fear and desperation that can set in," Kornspan said in a statement. "There can be a great temptation to jump at anything that appears to offer a chance for a cure." They especially take advantage of people's tendency to believe that "natural" cures and treatments are better than those developed by commercial pharmaceutical companies. But they're not only a waste of money — they can contain harmful ingredients.
For instance, "Everything Herbs" was advertising apricot kernels, which contain deadly cyanide. Apricot seeds were the basis for laetrile, an unproven but popular "alternative" cancer therapy sold online and in overseas clinics since the 1970s, despite much evidence it is worthless. "Contained within these kernels is a very small amount of a substance called nitriloside amygdalin. It goes directly to a cancer cell, stings it, and kills it," the FDA quoted the "Everything Herbs" site as saying. The website was down for repairs when NBC News investigated and a call to the firm's phone number yielded a voicemail saying the entire company was on vacation. Another site, DoctorVicks.com, sells a variety of herbs and supplements, including silymarin, also known as milk thistle. "Milk thistle's main ingredient silymarin has been found to support the liver in wondrous ways. It can help fix the damage done to the liver by alcohol or Tylenol, and can protect the liver from future damage," it claims. There is a compound that can help the damage done by Tylenol overdoses — it's called N-acetylcysteine (NAC) but it must be given immediately and by a medical professional.
Some studies have suggested silymarin may be helpful but it has not been approved and the dose has not been established. Dr. Vicks did not immediately respond to a request for comment from NBC News. The FDA has given the companies 15 days to come up with a plan to comply with FDA orders. The agency can prosecute and fine the companies and even seek prison terms. "The message to consumers is this: These products are untested. Some contain ingredients that may be a direct risk to your health," the FDA said. "The ingredients may interact in a dangerous way with professionally-prescribed treatments. They are not a substitute for appropriate treatments. Using these products can waste your money, and, more importantly, endanger your health."
"These companies used slick ads, videos, and other sophisticated marketing techniques, including testimonials about miraculous outcomes," the FDA's Donald Ashley and Douglas Stearn wrote in a blog post. "Often a single product was promoted as a treatment or cure for multiple diseases in humans and animals." The FDA has listed the 14 companies on its website and detailed the false claims they have made about their products, which include herbs, tinctures, supplements, teas and salves. The claims range from curing cancer to "detoxifying" the liver. t's illegal to make such claims without proving they are true and going through the FDA's process for verifying them. Just putting a little disclaimer at the bottom of an ad saying the FDA has not verified the claims doesn't cut it, the agency said.
"Hoping to skirt the law on a technicality, some sellers made false claims and then in small print provided a disclaimer that their products are not intended to diagnose, treat, cure or prevent any disease," Ashley and Stearn wrote. "Making such obvious claims and then saying later that you are not doing so might seem clever, but the technique does not comply with federal laws intended to protect public health." The companies are taking advantage of frightened cancer patients and their loved ones, said consumer safety officer Nicole Kornspan. And they make a lot of money doing it. Americans spend $30 billion a year on alternative therapies.
"Anyone who suffers from cancer, or knows someone who does, understands the fear and desperation that can set in," Kornspan said in a statement. "There can be a great temptation to jump at anything that appears to offer a chance for a cure." They especially take advantage of people's tendency to believe that "natural" cures and treatments are better than those developed by commercial pharmaceutical companies. But they're not only a waste of money — they can contain harmful ingredients.
For instance, "Everything Herbs" was advertising apricot kernels, which contain deadly cyanide. Apricot seeds were the basis for laetrile, an unproven but popular "alternative" cancer therapy sold online and in overseas clinics since the 1970s, despite much evidence it is worthless. "Contained within these kernels is a very small amount of a substance called nitriloside amygdalin. It goes directly to a cancer cell, stings it, and kills it," the FDA quoted the "Everything Herbs" site as saying. The website was down for repairs when NBC News investigated and a call to the firm's phone number yielded a voicemail saying the entire company was on vacation. Another site, DoctorVicks.com, sells a variety of herbs and supplements, including silymarin, also known as milk thistle. "Milk thistle's main ingredient silymarin has been found to support the liver in wondrous ways. It can help fix the damage done to the liver by alcohol or Tylenol, and can protect the liver from future damage," it claims. There is a compound that can help the damage done by Tylenol overdoses — it's called N-acetylcysteine (NAC) but it must be given immediately and by a medical professional.
Some studies have suggested silymarin may be helpful but it has not been approved and the dose has not been established. Dr. Vicks did not immediately respond to a request for comment from NBC News. The FDA has given the companies 15 days to come up with a plan to comply with FDA orders. The agency can prosecute and fine the companies and even seek prison terms. "The message to consumers is this: These products are untested. Some contain ingredients that may be a direct risk to your health," the FDA said. "The ingredients may interact in a dangerous way with professionally-prescribed treatments. They are not a substitute for appropriate treatments. Using these products can waste your money, and, more importantly, endanger your health."
Labels:
cancer cure,
cancer treatment
Location:
Houston, TX, USA
Thursday, February 2, 2017
Cancer Chemotherapy and Hair Loss: Why It Matters
Anna Crollman's reverse hair timeline says it all: Her short, stylish, frosted haircut 10 months after chemotherapy, her bald-as-an-egg scalp during chemotherapy and her thick, flowing brown locks before she began treatment for breast cancer.
In the hair-journey images on her My Cancer Chic blog, intended to help young women braving breast cancer and beyond, Crollman, now 29, exudes a sense of confidence. But through all the hardships of diagnosis, chemotherapy, mastectomy, breast reconstruction and more, Crollman says losing her hair was among the most traumatic.
Distressing Side Effect
With some types of chemotherapy, an unfortunate side effect is that hair follicles are killed along with the target cancer cells. Hair loss may occur only on the head or include eyelashes, eyebrows and body hair as well. Certain drugs used to treat breast cancer intravenously, such as Taxotere and Adriamycin, are more likely to cause hair loss or thinning. Some chemotherapy regimens used for later-stage breast cancer or other types of cancer don't cause hair loss, says Dr. Kathryn Ruddy, an oncologist, researcher and associate professor of oncology at the Mayo Clinic in Rochester, Minnesota.
However, she says, "the standard therapy regimens we give for early-stage breast cancer – meaning we think we can cure the disease with the chemotherapy – those unfortunately almost do universally cause hair loss." Ruddy tells her patients it usually takes about six months after the last dose of standard chemotherapy for the hair to grow back and for most people to feel comfortable without a wig. "Thankfully, most patients regain a full head of hair," she says. Hair usually grows back curlier, at least initially, and sometimes the color is different. While hair looks thinner while growing back, she says, most people end up with as much thickness as they had before. Chemo-related balding tends to bother women more than men. For some patients, Ruddy says, hair loss "can be the most troubling and difficult side effect of chemotherapy."
Beating Chemo to the Punch
Crollman, a graduate program coordinator with the Eshelman School of Pharmacy at the University of North Carolina–Chapel Hill, was diagnosed in July 2015. She was well-informed about chemotherapy side effects, including the impending hair loss. "As women, we use hair to define who we are," Crollman says. "And feeling like that part of your identity is going to be stripped away makes you feel very vulnerable and almost naked. To feel like you don't have that to hide behind. So I was very scared about that aspect of the chemotherapy." She decided to shave her head. "Cancer takes so much from you in terms of choices that you have, opportunities lost," she says. "Your body is going to be changing and you have to go through these treatments. Shaving my head was a way for me to regain some control of the situation and for me to choose when it was going to happen." Crollman and her husband hosted a head-shaving party at a local hair salon, which they had to themselves for the occasion.
They served wine and cheese to family and friends. First, Crollman shaved her husband's head. Next, a professional stylist gave Crollman a buzz cut. As prepared as she felt, she says it still felt traumatic. "Lots of tears," she recalls. The other shoe dropped when chemotherapy left its mark, Crollman says: "Then when it starts to fall out, you realize: OK, now I'm officially bald." "Most cancer centers recognize that this is a major psychological issue and we need to do as much as we can to support patients," Ruddy says. Nurses and other team members do a lot to educate patients on resources for hair loss. One step is writing a prescription for a wig, which is usually covered by insurance. The Mayo Clinic has an onsite wig shop. Even if patients chose not to get a wig there, Ruddy says, it's helpful to stop in because the staff is so knowledgeable about hair loss and hair coverings. Ask what your cancer center can do for you. Caps that cool the scalp during chemotherapy may help some women preserve their hair. An industry-funded study, reported in December at the San Antonio Breast Cancer Symposium, found among women with breast cancer who underwent four cycles of chemotherapy, those who used the scalp-cooling apparatus while receiving chemo were more likely to retain at least some of their hair.
But the close-fitting caps can cause headaches and are costly at more than $1,000 throughout treatment. Results vary with the caps, partially depending on the individual chemotherapy regime, Ruddy says, and it's unclear whether they're effective enough to make the discomfort worthwhile. "It's not that comfortable to wear basically an ice cap during chemotherapy, and it does extend the amount of time someone needs to get the infusion," she says.
Coping in Style
Doctors at the N.C. Cancer Hospital in Chapel Hill, where Crollman was treated, referred her to the in-hospital boutique to view the selection of wigs, scarves, wraps and hats. Crollman found that she preferred not having a wig in the same style or color as her pretreatment hair. When she first tried matching that look, she says, "It was horrible. It felt like a fraud." Instead, a shorter, lighter-colored wig felt much more comfortable, she says – like creating a new persona instead of trying to re-create what she'd lost. Individuality and sense of style don't disappear with a woman's hair.
Many women use head scarves, some homemade, although Crollman preferred not to. "Some women I know wear the head scarf and look beautiful and rock it and feel really confident that way, so more power to them," she says. About halfway through her treatment, Crollman decided to shed her wig and break out bald. "It was itchy," she says. "I was tired of wearing it. And I had spent the weekend at home sick, laying around. Something in me just switched, and I said, 'I'm just going to wear the bald head.'" Wigless, she went to work, where colleagues were supportive as ever. From that point on, she never wore a wig or scarf again. Crollman wants to help other young women as they continue to work, socialize and simply care about their appearance in the midst of cancer treatment. In addition to blogging, she serves as a Living Beyond Breast Cancer Young Advocate. She's still receiving some treatment, and while she has good days and bad days, she says, "Mentally, I'm in a really good place now."
Distressing Side Effect
With some types of chemotherapy, an unfortunate side effect is that hair follicles are killed along with the target cancer cells. Hair loss may occur only on the head or include eyelashes, eyebrows and body hair as well. Certain drugs used to treat breast cancer intravenously, such as Taxotere and Adriamycin, are more likely to cause hair loss or thinning. Some chemotherapy regimens used for later-stage breast cancer or other types of cancer don't cause hair loss, says Dr. Kathryn Ruddy, an oncologist, researcher and associate professor of oncology at the Mayo Clinic in Rochester, Minnesota.
However, she says, "the standard therapy regimens we give for early-stage breast cancer – meaning we think we can cure the disease with the chemotherapy – those unfortunately almost do universally cause hair loss." Ruddy tells her patients it usually takes about six months after the last dose of standard chemotherapy for the hair to grow back and for most people to feel comfortable without a wig. "Thankfully, most patients regain a full head of hair," she says. Hair usually grows back curlier, at least initially, and sometimes the color is different. While hair looks thinner while growing back, she says, most people end up with as much thickness as they had before. Chemo-related balding tends to bother women more than men. For some patients, Ruddy says, hair loss "can be the most troubling and difficult side effect of chemotherapy."
Beating Chemo to the Punch
Crollman, a graduate program coordinator with the Eshelman School of Pharmacy at the University of North Carolina–Chapel Hill, was diagnosed in July 2015. She was well-informed about chemotherapy side effects, including the impending hair loss. "As women, we use hair to define who we are," Crollman says. "And feeling like that part of your identity is going to be stripped away makes you feel very vulnerable and almost naked. To feel like you don't have that to hide behind. So I was very scared about that aspect of the chemotherapy." She decided to shave her head. "Cancer takes so much from you in terms of choices that you have, opportunities lost," she says. "Your body is going to be changing and you have to go through these treatments. Shaving my head was a way for me to regain some control of the situation and for me to choose when it was going to happen." Crollman and her husband hosted a head-shaving party at a local hair salon, which they had to themselves for the occasion.
They served wine and cheese to family and friends. First, Crollman shaved her husband's head. Next, a professional stylist gave Crollman a buzz cut. As prepared as she felt, she says it still felt traumatic. "Lots of tears," she recalls. The other shoe dropped when chemotherapy left its mark, Crollman says: "Then when it starts to fall out, you realize: OK, now I'm officially bald." "Most cancer centers recognize that this is a major psychological issue and we need to do as much as we can to support patients," Ruddy says. Nurses and other team members do a lot to educate patients on resources for hair loss. One step is writing a prescription for a wig, which is usually covered by insurance. The Mayo Clinic has an onsite wig shop. Even if patients chose not to get a wig there, Ruddy says, it's helpful to stop in because the staff is so knowledgeable about hair loss and hair coverings. Ask what your cancer center can do for you. Caps that cool the scalp during chemotherapy may help some women preserve their hair. An industry-funded study, reported in December at the San Antonio Breast Cancer Symposium, found among women with breast cancer who underwent four cycles of chemotherapy, those who used the scalp-cooling apparatus while receiving chemo were more likely to retain at least some of their hair.
But the close-fitting caps can cause headaches and are costly at more than $1,000 throughout treatment. Results vary with the caps, partially depending on the individual chemotherapy regime, Ruddy says, and it's unclear whether they're effective enough to make the discomfort worthwhile. "It's not that comfortable to wear basically an ice cap during chemotherapy, and it does extend the amount of time someone needs to get the infusion," she says.
Coping in Style
Doctors at the N.C. Cancer Hospital in Chapel Hill, where Crollman was treated, referred her to the in-hospital boutique to view the selection of wigs, scarves, wraps and hats. Crollman found that she preferred not having a wig in the same style or color as her pretreatment hair. When she first tried matching that look, she says, "It was horrible. It felt like a fraud." Instead, a shorter, lighter-colored wig felt much more comfortable, she says – like creating a new persona instead of trying to re-create what she'd lost. Individuality and sense of style don't disappear with a woman's hair.
Many women use head scarves, some homemade, although Crollman preferred not to. "Some women I know wear the head scarf and look beautiful and rock it and feel really confident that way, so more power to them," she says. About halfway through her treatment, Crollman decided to shed her wig and break out bald. "It was itchy," she says. "I was tired of wearing it. And I had spent the weekend at home sick, laying around. Something in me just switched, and I said, 'I'm just going to wear the bald head.'" Wigless, she went to work, where colleagues were supportive as ever. From that point on, she never wore a wig or scarf again. Crollman wants to help other young women as they continue to work, socialize and simply care about their appearance in the midst of cancer treatment. In addition to blogging, she serves as a Living Beyond Breast Cancer Young Advocate. She's still receiving some treatment, and while she has good days and bad days, she says, "Mentally, I'm in a really good place now."
Labels:
cancer treatment,
chemotherapy hair loss
Location:
Houston, TX, USA
Monday, December 12, 2016
Loneliness may sabotage breast cancer survival, study finds
Loneliness may impede long-term breast cancer survival, a new study suggests.
In the years after treatment, women who don’t have strong social ties are more likely to have their cancer return or die from it than women with friends and a support network, the researchers found.
Reviewing data on nearly 10,000 breast cancer patients, the researchers linked isolation with a 40 percent higher risk of cancer recurrence compared to socially connected women.
These solitary women also had a 60 percent increased risk of dying from breast cancer and a 70 percent increased risk of dying from any cause, the study found. The results weren’t unexpected, the researchers said. “It is well established that women generally and those with breast cancer with greater social ties have a lower risk of death overall,” said lead researcher Candyce Kroenke. She’s with Kaiser Permanente’s Division of Research in Oakland, Calif.
People are social animals, said Kassandra Alcaraz, strategic director for health equity research at the American Cancer Society. “We were not meant to be isolated, so the benefits we get from relationships with others and being part of a community are not surprising,” she said. “We know that social relationships are important to general health and well-being.” Exactly why this is so isn’t entirely clear, Alcaraz said. “Having social ties may provide access to real assistance, like having someone to take you to the doctor or having someone to talk to about your concerns or connecting you with resources that can help you cope with the cancer,” she said. Also, social well-being is correlated with physical well-being, Alcaraz added.
Having connections to others helps reduce stress and depression and thus leads to better health outcomes, she said. “We need to think of health in a more expansive way. Social influences can be just as important as other risk factors, such as obesity and smoking,” Alcaraz said. Kroencke and her colleagues agreed, saying doctors should consider a woman’s social supports when making predictions for her recovery. For this study, the researchers looked at a woman’s social connections in the two years after her breast cancer diagnosis to see how having friends, a spouse, relatives or community ties might affect her survival.
The report was published online Dec. 12 in the journal Cancer. Data was collected on just over 9,000 women. Over an average follow-up of 11 years, more than 1,400 cancers returned. Also, more than 1,500 women died, nearly 1,000 from breast cancer, the researchers found. The links between social connections and prognosis were strongest among women with earlier stage cancer, the researchers said. Also, specific associations differed by age, race, ethnicity and country, Kroenke said. For example, ties to relatives and friends predicted lower breast cancer deaths for nonwhite women. And marriage predicted lower breast cancer deaths only among older white women.
In addition, community ties predicted better outcomes in older white and Asian women. “Our findings demonstrate the generally beneficial influence of women’s social ties on breast cancer outcomes, including recurrence and breast cancer death,” Kroenke said. The results don’t mean that loners are doomed to an early death, nor do they show a direct cause-and-effect relationship between isolation and worse survival. Still, it’s important for doctors and other health care workers to help patients connect with support groups and other programs so they won’t remain socially isolated, Alcaraz said. “Social ties have positive health benefits, and social isolation is detrimental to health,” she said. “And it is not unique to breast cancer or to cancer for that matter.”
These solitary women also had a 60 percent increased risk of dying from breast cancer and a 70 percent increased risk of dying from any cause, the study found. The results weren’t unexpected, the researchers said. “It is well established that women generally and those with breast cancer with greater social ties have a lower risk of death overall,” said lead researcher Candyce Kroenke. She’s with Kaiser Permanente’s Division of Research in Oakland, Calif.
People are social animals, said Kassandra Alcaraz, strategic director for health equity research at the American Cancer Society. “We were not meant to be isolated, so the benefits we get from relationships with others and being part of a community are not surprising,” she said. “We know that social relationships are important to general health and well-being.” Exactly why this is so isn’t entirely clear, Alcaraz said. “Having social ties may provide access to real assistance, like having someone to take you to the doctor or having someone to talk to about your concerns or connecting you with resources that can help you cope with the cancer,” she said. Also, social well-being is correlated with physical well-being, Alcaraz added.
Having connections to others helps reduce stress and depression and thus leads to better health outcomes, she said. “We need to think of health in a more expansive way. Social influences can be just as important as other risk factors, such as obesity and smoking,” Alcaraz said. Kroencke and her colleagues agreed, saying doctors should consider a woman’s social supports when making predictions for her recovery. For this study, the researchers looked at a woman’s social connections in the two years after her breast cancer diagnosis to see how having friends, a spouse, relatives or community ties might affect her survival.
The report was published online Dec. 12 in the journal Cancer. Data was collected on just over 9,000 women. Over an average follow-up of 11 years, more than 1,400 cancers returned. Also, more than 1,500 women died, nearly 1,000 from breast cancer, the researchers found. The links between social connections and prognosis were strongest among women with earlier stage cancer, the researchers said. Also, specific associations differed by age, race, ethnicity and country, Kroenke said. For example, ties to relatives and friends predicted lower breast cancer deaths for nonwhite women. And marriage predicted lower breast cancer deaths only among older white women.
In addition, community ties predicted better outcomes in older white and Asian women. “Our findings demonstrate the generally beneficial influence of women’s social ties on breast cancer outcomes, including recurrence and breast cancer death,” Kroenke said. The results don’t mean that loners are doomed to an early death, nor do they show a direct cause-and-effect relationship between isolation and worse survival. Still, it’s important for doctors and other health care workers to help patients connect with support groups and other programs so they won’t remain socially isolated, Alcaraz said. “Social ties have positive health benefits, and social isolation is detrimental to health,” she said. “And it is not unique to breast cancer or to cancer for that matter.”
Labels:
breast cancer,
cancer treatment,
survival
Location:
Houston, TX, USA
Tuesday, December 6, 2016
Lymphedema and Breast Cancer: When Is Risk Greatest?
The time course for developing lymphedema depends on the type of breast cancer treatment, but the risk peaks between 24 and 36 months post therapy, regardless of treatment type, according to new research.
Receipt of radiation therapy (RT) is also a key to the timing.
"Lymphedema develops earlier in patients who receive radiation, especially those receiving regional lymph node radiation," said the study's lead author, Susan McDuff, MD, PhD, a resident in radiation oncology at the Massachusetts General Hospital (MGH) Cancer Center in Boston.
Lymphedema can be "an incredibly morbid" complication following treatment for breast cancer and is an ongoing source of anxiety for survivors, she said here at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting. To help patients know when they may be "out of the woods," Dr McDuff and colleagues undertook a cohort study to determine whether there is a period when patients are at greatest risk. First, they looked at cumulative incidence.
The team analyzed the records of 1495 patients seen between 2005 and 2016 in a prospective lymphedema screening program at MGH. The time it took to reach 5% cumulative incidence by treatment group was 32 months for surgery alone and 15 months for RT (P = .02) However, a further look at the data revealed that patients who received regional lymph node radiation (RLNR) reached the 5% cumulative incidence in only 6 months vs 37 months for those who received local RT (P < .0001). There was a median follow-up of 3.9 years and a cumulative lymphedema incidence of 11.4% in the study population. Nearly three quarters (73%) of the patients received RT as a component of their treatment. To pinpoint risk over time, the researchers looked at the percentage of patients in various treatment groups who were diagnosed with lymphedema in each year during the first 5 years post therapy. This was done by plotting the annual hazard rate for the treatment groups. All patients received some mix of axillary surgery and RT.
The groups were as follows: no axillary surgery (n = 180); sentinel lymph node biopsy (SLNB) plus or minus local RT (n = 899); SLNB plus regional lymph node radiation (RLNR) (n = 46); and axillary lymph node dissection (ALND) plus or minus local RT (n = 132); and ALND plus RLNR (n = 264). "The timing of the risk appears to be the most significant within the first 2 to 3 years after treatment," summarized Dr McDuff.
The new study addresses an important clinical question, said Abram Recht, MD, professor of radiation oncology at Harvard Medical School in Boston, who acted as an adviser to the study authors. "If you are going to do surveillance, how long do you have to do it?" he commented to Medscape Medical News. "You can expect that most patients who undergo sentinel lymph node biopsy with or without local RT, which is the largest treatment group, may not need active monitoring past 2 years," he concluded. "The period of the greatest risk is the first 3 years," said Dr Recht, echoing Dr McDuff. "If lymphedema hasn't developed by 5 years, then it probably won't happen," he added. The new results are an argument for "personalizing" a lymphedema monitoring program, said Dr McDuff, adding that more follow-up is needed for high-risk groups.
The goal is early identification and intervention. Shannon MacDonald, MD, associate professor of radiation oncology at Harvard, who acted as discussant of the study, said that the hope with monitoring is "that an earlier intervention for lymphedema would improve outcome." Dr MacDonald told Medscape Medical News that the new study results will also "allow patients to have some alleviation of anxiety as to when to expect lymphedema if it occurs," she said. The findings could also influence "when clinicians have patients come in for monitoring," Dr MacDonald added. This "very large" study makes a "meaningful contribution" to clinical knowledge, in part because there are "limited" data on timing, she said. Lymphedema is less common than in the past, owing to improvements in surgical management, but inaccuracy of measurements has plagued estimates of the incidence of lymphedema, Dr MacDonald said.
The new MGH study used a perometer, a tool that employs infrared technology to objectively measure the limb, which is "more likely to be accurate than a tape measure or other modalities," she said. The perometer was used to perform prospective arm volume measurements of the study patients preoperatively and then postoperatively and in follow-ups at regular intervals. Lymphedema was defined as a >10% relative volume increase occurring >3 months postoperatively. The treatments for lymphedema in the cohort included compression sleeves (88%), manual decompression (52%), and physical therapy–directed exercise (89%). "Patients worry a lot about lymphedema" concluded Dr Recht. "It's a really hard thing in survivorship," agreed Dr McDuff.
Lymphedema can be "an incredibly morbid" complication following treatment for breast cancer and is an ongoing source of anxiety for survivors, she said here at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting. To help patients know when they may be "out of the woods," Dr McDuff and colleagues undertook a cohort study to determine whether there is a period when patients are at greatest risk. First, they looked at cumulative incidence.
The team analyzed the records of 1495 patients seen between 2005 and 2016 in a prospective lymphedema screening program at MGH. The time it took to reach 5% cumulative incidence by treatment group was 32 months for surgery alone and 15 months for RT (P = .02) However, a further look at the data revealed that patients who received regional lymph node radiation (RLNR) reached the 5% cumulative incidence in only 6 months vs 37 months for those who received local RT (P < .0001). There was a median follow-up of 3.9 years and a cumulative lymphedema incidence of 11.4% in the study population. Nearly three quarters (73%) of the patients received RT as a component of their treatment. To pinpoint risk over time, the researchers looked at the percentage of patients in various treatment groups who were diagnosed with lymphedema in each year during the first 5 years post therapy. This was done by plotting the annual hazard rate for the treatment groups. All patients received some mix of axillary surgery and RT.
The groups were as follows: no axillary surgery (n = 180); sentinel lymph node biopsy (SLNB) plus or minus local RT (n = 899); SLNB plus regional lymph node radiation (RLNR) (n = 46); and axillary lymph node dissection (ALND) plus or minus local RT (n = 132); and ALND plus RLNR (n = 264). "The timing of the risk appears to be the most significant within the first 2 to 3 years after treatment," summarized Dr McDuff.
The new study addresses an important clinical question, said Abram Recht, MD, professor of radiation oncology at Harvard Medical School in Boston, who acted as an adviser to the study authors. "If you are going to do surveillance, how long do you have to do it?" he commented to Medscape Medical News. "You can expect that most patients who undergo sentinel lymph node biopsy with or without local RT, which is the largest treatment group, may not need active monitoring past 2 years," he concluded. "The period of the greatest risk is the first 3 years," said Dr Recht, echoing Dr McDuff. "If lymphedema hasn't developed by 5 years, then it probably won't happen," he added. The new results are an argument for "personalizing" a lymphedema monitoring program, said Dr McDuff, adding that more follow-up is needed for high-risk groups.
The goal is early identification and intervention. Shannon MacDonald, MD, associate professor of radiation oncology at Harvard, who acted as discussant of the study, said that the hope with monitoring is "that an earlier intervention for lymphedema would improve outcome." Dr MacDonald told Medscape Medical News that the new study results will also "allow patients to have some alleviation of anxiety as to when to expect lymphedema if it occurs," she said. The findings could also influence "when clinicians have patients come in for monitoring," Dr MacDonald added. This "very large" study makes a "meaningful contribution" to clinical knowledge, in part because there are "limited" data on timing, she said. Lymphedema is less common than in the past, owing to improvements in surgical management, but inaccuracy of measurements has plagued estimates of the incidence of lymphedema, Dr MacDonald said.
The new MGH study used a perometer, a tool that employs infrared technology to objectively measure the limb, which is "more likely to be accurate than a tape measure or other modalities," she said. The perometer was used to perform prospective arm volume measurements of the study patients preoperatively and then postoperatively and in follow-ups at regular intervals. Lymphedema was defined as a >10% relative volume increase occurring >3 months postoperatively. The treatments for lymphedema in the cohort included compression sleeves (88%), manual decompression (52%), and physical therapy–directed exercise (89%). "Patients worry a lot about lymphedema" concluded Dr Recht. "It's a really hard thing in survivorship," agreed Dr McDuff.
Tuesday, November 8, 2016
Thursday, October 27, 2016
Health insurance shirks its duty to women with breast cancer complications
Karen Chavez
When I wear sleeveless tops, there isn’t a day when I’m not asked about my lymphedema garments. These are a full-length sleeve and a fingerless glove on my left arm. “Do you golf?” “Are you a bowler?” “What’s wrong with your arm?” and even, “Cool sleeve, where did you get it?” Um, the Asheville Orthopedic Appliance Co.
I wear the garments, not as a fashion statement, not to bowl, but to control the non-stop pain and swelling in my left arm and hand, known as lymphedema. Over the past three years of wearing the garments, I now use the questions as a teaching moment. Lymphedema is a chronic disease that results in a backup of lymph fluid (which carries away the waste from the blood stream). It occurs when the lymphatic system is damaged, said Emily Jones, an occupational therapist at CarePartners. In my case, the damage was caused by breast cancer surgery and the removal of lymph nodes from under my arm. There is no cure for lymphedema.
Once you have it, you have it forever. An estimated 3 million-5 million people Americans suffer from lymphedema. Two out of five breast cancer patients will develop lymphedema within five years of surgery. With lymphedema, I cannot type. I wouldn’t be able to write this story, which is my livelihood. But there is treatment. The two most effective are manual lymphatic drainage, performed by a physical therapist specializing in lymphedema, and compression garments. The garments require a doctor’s prescription and are custom made. They are about $328 for one sleeve and one glove. I need two at a time, $656 – one to wear while the other is being washed. (They are tight to the skin, get sweaty and dirty and need to be changed daily, kind of like underwear). I need new pairs twice a year because they stretch out, get damaged and then are no longer effective. That’s about $1,312 a year. It is cost prohibitive. My former health insurance paid for them.
My new insurance company – Blue Cross Blue Shield of Texas – does not cover compression garments. When I told the BCBS customer service person that I have breast cancer and cannot function without them and can’t afford them, on top of my ever-growing mountain of breast cancer-related debt, she said “those are the rules.’’ Well, North Carolina has its own rules. Actually, it has a law. Passed by the General Assembly in 2009, HB 535 states that every health benefit plan in the state must provide coverage for the diagnosis, evaluation, and treatment of lymphedema, including benefits for equipment, supplies, complex decongestive therapy, and gradient compression garments. North Carolina and Virginia and the only two states in the country with such laws. Bravo.
I told the BCBS rep about that and that the N.C. law should cover me. She said it did not, since the company is based in Texas. Sound barbaric? Heather Ferguson thought so. A mom of two from Charlotte, one of her sons was born with primary lymphedema in both legs. He was prescribed his first compression garment at age 7 months. Ferguson’s insurance denied it. Not a woman to be messed with, Ferguson reached out to her state representative, Tricia Cotham, D-Mecklenburg. Cotham helped Ferguson with the appeal, which only gave her one year of payment. Now 10, he needs to wear the knee-high socks every day. He will need them for life. Ferguson continued to work with state representatives until the lymphedema law passed.
She formed the Lymphedema Advocacy Group. Now she has taken her cause to Congress. Introduced in 2010, the Lymphedema Treatment Act would amend a section of the Social Security act to provide for Medicare coverage for lymphedema compression items. That would extend to all states, even Texas. The bill has 249 House co-sponsors, including Rep. Mark Meadows, R-Jackson, and 28 senators, including Thom Tillis. Sen. Richard Burr has not signed on. “It already has a large amount of bipartisan support,” Ferguson told me. “It’s a win-win for everyone. It improves patient care and quality of life, and provides a net saving to Medicare. We’re paying for so many things that can be prevented if we manage the disease from the start.” Even with my sleeve and glove, I often have to raise my arm to further control the swelling. Then people ask, “Do you have a question?” Yes. Why won’t my health insurance pay for my lymphedema sleeves?
When I wear sleeveless tops, there isn’t a day when I’m not asked about my lymphedema garments. These are a full-length sleeve and a fingerless glove on my left arm. “Do you golf?” “Are you a bowler?” “What’s wrong with your arm?” and even, “Cool sleeve, where did you get it?” Um, the Asheville Orthopedic Appliance Co.
I wear the garments, not as a fashion statement, not to bowl, but to control the non-stop pain and swelling in my left arm and hand, known as lymphedema. Over the past three years of wearing the garments, I now use the questions as a teaching moment. Lymphedema is a chronic disease that results in a backup of lymph fluid (which carries away the waste from the blood stream). It occurs when the lymphatic system is damaged, said Emily Jones, an occupational therapist at CarePartners. In my case, the damage was caused by breast cancer surgery and the removal of lymph nodes from under my arm. There is no cure for lymphedema.
Once you have it, you have it forever. An estimated 3 million-5 million people Americans suffer from lymphedema. Two out of five breast cancer patients will develop lymphedema within five years of surgery. With lymphedema, I cannot type. I wouldn’t be able to write this story, which is my livelihood. But there is treatment. The two most effective are manual lymphatic drainage, performed by a physical therapist specializing in lymphedema, and compression garments. The garments require a doctor’s prescription and are custom made. They are about $328 for one sleeve and one glove. I need two at a time, $656 – one to wear while the other is being washed. (They are tight to the skin, get sweaty and dirty and need to be changed daily, kind of like underwear). I need new pairs twice a year because they stretch out, get damaged and then are no longer effective. That’s about $1,312 a year. It is cost prohibitive. My former health insurance paid for them.
My new insurance company – Blue Cross Blue Shield of Texas – does not cover compression garments. When I told the BCBS customer service person that I have breast cancer and cannot function without them and can’t afford them, on top of my ever-growing mountain of breast cancer-related debt, she said “those are the rules.’’ Well, North Carolina has its own rules. Actually, it has a law. Passed by the General Assembly in 2009, HB 535 states that every health benefit plan in the state must provide coverage for the diagnosis, evaluation, and treatment of lymphedema, including benefits for equipment, supplies, complex decongestive therapy, and gradient compression garments. North Carolina and Virginia and the only two states in the country with such laws. Bravo.
I told the BCBS rep about that and that the N.C. law should cover me. She said it did not, since the company is based in Texas. Sound barbaric? Heather Ferguson thought so. A mom of two from Charlotte, one of her sons was born with primary lymphedema in both legs. He was prescribed his first compression garment at age 7 months. Ferguson’s insurance denied it. Not a woman to be messed with, Ferguson reached out to her state representative, Tricia Cotham, D-Mecklenburg. Cotham helped Ferguson with the appeal, which only gave her one year of payment. Now 10, he needs to wear the knee-high socks every day. He will need them for life. Ferguson continued to work with state representatives until the lymphedema law passed.
She formed the Lymphedema Advocacy Group. Now she has taken her cause to Congress. Introduced in 2010, the Lymphedema Treatment Act would amend a section of the Social Security act to provide for Medicare coverage for lymphedema compression items. That would extend to all states, even Texas. The bill has 249 House co-sponsors, including Rep. Mark Meadows, R-Jackson, and 28 senators, including Thom Tillis. Sen. Richard Burr has not signed on. “It already has a large amount of bipartisan support,” Ferguson told me. “It’s a win-win for everyone. It improves patient care and quality of life, and provides a net saving to Medicare. We’re paying for so many things that can be prevented if we manage the disease from the start.” Even with my sleeve and glove, I often have to raise my arm to further control the swelling. Then people ask, “Do you have a question?” Yes. Why won’t my health insurance pay for my lymphedema sleeves?
Labels:
breast cancer,
cancer treatment,
Lymphedema
Location:
Houston, TX, USA
Tuesday, October 11, 2016
Breast Cancer Treatment Costs Vary Wildly, Study Finds
It should have been a no-brainer — a routine test to confirm that a 50-something teacher was now, officially, a breast cancer survivor. But the patient balked.
The surprise encounter got Dr. Sharon Giordano curious and she embarked on a study that has found that the cost of cancer treatment varies wildly, with no apparent rhyme or reason.
The variation adds up to $1 billion a year that insurance companies, patients and government health plans are needlessly paying to treat breast cancer, Giordano and colleagues at the MD Anderson Cancer Center report on Monday in the journal Cancer. Patients often get stuck with thousands of dollars in bills that can take years to pay off. "One of the reasons I started on this project is I had a patient with triple-negative breast cancer," Giordano told NBC News. "She was just finishing her five-year follow-up after treatment and was transitioning into survivorship. We talked about ordering an additional test. She was reluctant to get it." Why would anyone want to skip a test that could put her in the clear? "She shared with me that she was still on a payment plan, still trying to pay off the debt from her breast cancer treatment five years earlier," Giordano said.
"That really shocked me. I didn't know. I think it cured her but it left her with this huge debt that I was completely unaware of." In fact, the costs can get so high that some patients may skip treatments. "If they have a higher copay and it costs more, then they are less likely to take it," Giordano said. "There are pretty clear data that show the more it costs, the less people take it." As a working oncologist, Giordano knew there are almost always a variety of choices for treating breast cancer. She wanted to see if there was an easy way for patients and their doctors to pick the least expensive treatment that would still be effective. She was stunned at what she found. The team went through insurance claims filed by more than 14,000 breast cancer patients between 2008 and 2012 and found expenses across a single class of drugs varied by as much as $46,000.
"There were big variations in the cost of treatments we could prescribe," Giordano said.
Even more surprising: Some of the more effective and least toxic treatments were, in fact, cheaper.
"There is one chemotherapy regimen called TAC," Giordano said. That's short for Taxotere plus adriamycin plus cyclophosphamide — three different chemotherapy drugs that hit the cancer in different ways.
"It was both one of the highest cost and one of the highest toxicity regimens," she said.
Swapping a related drug called paclitaxel for Taxotere cut both the side effects and the costs, Giordano said. "It's almost $15,000 cheaper," she said.
"I think most people would think those pretty equivalent in terms of efficacy," she added.
But it wasn't easy to find this out.
"For me, working at a hospital, I don't really see that at all. I don't have an easy way to access what the costs would be," she said. Even treatments that should be cheap varied widely in cost. "We give a pill called an aromatase inhibitor that blocks estrogen after chemotherapy. There are three different ones that are all approved and they are probably equivalent," Giordano said. These pills reduce the chance that tumors will come back in the other breast. "Depending on what insurance plan (a patient has) one would be more costly and one would be less costly.
Doctors should try to find out. The problem is, it is time-consuming," Giordano said. And how much a patient ended up paying herself varied wildly depending on which insurance plan she had. "I was somewhat surprised at the relatively high costs patients were bearing — around $3,000 out of pocket on average," she said. "What I think was more concerning was that top quarter, top 10 percent of patients are getting really hefty bills costing them $10,000 or more." Not surprisingly, people with so-called catastrophic health insurance plans, which charge low premiums but which also don't reimburse for much, paid the most out of pocket. It adds up.
"Expenditures for cancer care have grown from $72 billion in 2004 to $125 billion in 2010 and are estimated to reach $158 billion by 2020," Giordano's team wrote. "The costs of cancer care are increasing at an unsustainable rate — two to three times faster than other health care costs. Patients' out-of-pocket costs have also been rapidly increasing." The findings ring true to Peggy Johnson, a breast cancer survivor in Wichita, Kansas who's also an advocate for the breast cancer charity Susan G. Komen For the Cure. Johnson, who was a breast cancer advocate long before she herself was diagnosed, kept careful track of her own medical bills as she went through treatment. She had four rounds of chemotherapy for triple-negative breast cancer and 35 radiation treatments.
"The cost of my bills was $200,000 and a few cents," Johnson said. "The insurance company negotiated it down. They paid $60,000." Johnson ended up paying $3,000 out of pocket for co-insurance and counts herself lucky because she had insurance through her employer. "Many people in the United States who don't have health insurance would have been billed the full $200,000, and they would have been expected to pay the $200,000," she said. Related: Good Luck Finding Out What an MRI Costs Many patients would just delay treatment and wait until their cancer progressed, which ends up costing even more to treat. And patients may end up going on Medicaid and costing the state and federal government plan extra money for treating advanced cancer.
Both Giordano and Johnson say it's very difficult to find out ahead of time what each particular insurance plan will pay, and what each hospital, clinic or physician will charge, for various treatments. "This is everybody's problem," Johnson said. "I know women who have lost their homes because they couldn't pay their medical bills." Studies have shown that medical bills are one of the leading causes of personal bankruptcy.
The variation adds up to $1 billion a year that insurance companies, patients and government health plans are needlessly paying to treat breast cancer, Giordano and colleagues at the MD Anderson Cancer Center report on Monday in the journal Cancer. Patients often get stuck with thousands of dollars in bills that can take years to pay off. "One of the reasons I started on this project is I had a patient with triple-negative breast cancer," Giordano told NBC News. "She was just finishing her five-year follow-up after treatment and was transitioning into survivorship. We talked about ordering an additional test. She was reluctant to get it." Why would anyone want to skip a test that could put her in the clear? "She shared with me that she was still on a payment plan, still trying to pay off the debt from her breast cancer treatment five years earlier," Giordano said.
"That really shocked me. I didn't know. I think it cured her but it left her with this huge debt that I was completely unaware of." In fact, the costs can get so high that some patients may skip treatments. "If they have a higher copay and it costs more, then they are less likely to take it," Giordano said. "There are pretty clear data that show the more it costs, the less people take it." As a working oncologist, Giordano knew there are almost always a variety of choices for treating breast cancer. She wanted to see if there was an easy way for patients and their doctors to pick the least expensive treatment that would still be effective. She was stunned at what she found. The team went through insurance claims filed by more than 14,000 breast cancer patients between 2008 and 2012 and found expenses across a single class of drugs varied by as much as $46,000.
![]() |
| Dr. Regina Hampton prepares to insert a balloon catheter into a patient's breast for radiation treatment in Lanham, Maryland Marvin Joseph / The Washington Post/Getty Images |
"For me, working at a hospital, I don't really see that at all. I don't have an easy way to access what the costs would be," she said. Even treatments that should be cheap varied widely in cost. "We give a pill called an aromatase inhibitor that blocks estrogen after chemotherapy. There are three different ones that are all approved and they are probably equivalent," Giordano said. These pills reduce the chance that tumors will come back in the other breast. "Depending on what insurance plan (a patient has) one would be more costly and one would be less costly.
Doctors should try to find out. The problem is, it is time-consuming," Giordano said. And how much a patient ended up paying herself varied wildly depending on which insurance plan she had. "I was somewhat surprised at the relatively high costs patients were bearing — around $3,000 out of pocket on average," she said. "What I think was more concerning was that top quarter, top 10 percent of patients are getting really hefty bills costing them $10,000 or more." Not surprisingly, people with so-called catastrophic health insurance plans, which charge low premiums but which also don't reimburse for much, paid the most out of pocket. It adds up.
"Expenditures for cancer care have grown from $72 billion in 2004 to $125 billion in 2010 and are estimated to reach $158 billion by 2020," Giordano's team wrote. "The costs of cancer care are increasing at an unsustainable rate — two to three times faster than other health care costs. Patients' out-of-pocket costs have also been rapidly increasing." The findings ring true to Peggy Johnson, a breast cancer survivor in Wichita, Kansas who's also an advocate for the breast cancer charity Susan G. Komen For the Cure. Johnson, who was a breast cancer advocate long before she herself was diagnosed, kept careful track of her own medical bills as she went through treatment. She had four rounds of chemotherapy for triple-negative breast cancer and 35 radiation treatments.
"The cost of my bills was $200,000 and a few cents," Johnson said. "The insurance company negotiated it down. They paid $60,000." Johnson ended up paying $3,000 out of pocket for co-insurance and counts herself lucky because she had insurance through her employer. "Many people in the United States who don't have health insurance would have been billed the full $200,000, and they would have been expected to pay the $200,000," she said. Related: Good Luck Finding Out What an MRI Costs Many patients would just delay treatment and wait until their cancer progressed, which ends up costing even more to treat. And patients may end up going on Medicaid and costing the state and federal government plan extra money for treating advanced cancer.
Both Giordano and Johnson say it's very difficult to find out ahead of time what each particular insurance plan will pay, and what each hospital, clinic or physician will charge, for various treatments. "This is everybody's problem," Johnson said. "I know women who have lost their homes because they couldn't pay their medical bills." Studies have shown that medical bills are one of the leading causes of personal bankruptcy.
Location:
Houston, TX, USA
Thursday, September 29, 2016
New technology may help women with breast cancer forego chemotherapy
For women who are diagnosed with breast cancer every year in the U.S., a leading cause of cancer death among Hispanic women, one of the toughest choices to make is what type of treatment to choose.
A new test, called MammaPrint, is making it possible so women could forego chemotherapy. Such was the case for 46-year-old Zaida Vazquez when she was diagnosed with breast cancer this May. Breast cancer is the most commonly diagnosed cancer. Among Hispanic women, breast cancer will be the leading cause of cancer death this year (16 percent), followed by cancers of the lung (13 percent) and colorectum (9 percent), according to the American Cancer Society. Vasquez had surgery in July and then opted for chemotherapy – but stopped midway because she said it made her feel terrible.
Her days were ridden with nausea and exhaustion. That was when her oncologist, Dr. Mayra Rivera, suggested forgoing chemotherapy based on her MammaPrint results that analyzed 70 genes associated with a breast tumor’s chance of metastasizing. “MammaPrint gives me a biology footprint of the tumor,” said Dr. Rivera of Puerto Rico. “And, with patients like Zaida in the early stages of their breast cancer, also known as low risk, this test would benefit more women like her.” MammaPrint is among a growing number of tests attracting interest in the medical world because it lets women know if they could avoid chemotherapy with little risk that they’ll relapse. The tests examine a woman’s genes to determine whether the cancer has a chance of spreading. The tests and MammaPrint gained stature last month when a study exploring its effectiveness was published in The New England Journal of Medicine.
MammaPrint was used in the study, called MINDACT, which analyzed 6,693 breast cancer patients across 112 centers in Europe with newly diagnosed early-stage breast cancer. J. Leonard Lichtenfeld, deputy chief medical officer for the American Cancer Society, said these types of tests are not new. Lichtenfeld said that in the late 90s, there was a substantial amount of tests being developed that looked into the tumor tissue to predict how it would behave over time. Similar to MammaPrint’s approach was Oncotype DX, which took off but only analyzed 21 genes.
MammaPrint looks into the activity of 70 genes. MammaPrint is lesser known and used less often, but has become more popular the past few years. Still, it’s stirred discussion in the medical community because the tests are not 100 percent accurate and could falsely tell a woman she doesn’t need chemotherapy when she actually does. Others, however, believe it will spare thousands of women with early-stage breast cancer the painful – and expensive – experience of going through chemotherapy. The Journal of Medicine article said the MammaPrint clinical trial offers probabilities and not necessarily concrete guidance.
“The reality is that there haven’t been real life trials over an extended period of time to show that these tests work the way they are supposed to work,” Lichtenfeld said. The first author of the MINDACT study said it’s worth noting that this is the first clinical trial of its kind. “There hasn’t been another clinical trial wherein diagnostic tests were evaluated like this, that looked into the biology of the disease, for as long as we did,” said Dr. Laura van ’t Veer, chief research officer of the study. Of the European countries involved in the study, Spain was one of the most active in the trial coming in at about 700 participants.
In centers in Barcelona and Madrid, MammaPrint is already being used frequently. “Everyone can agree that avoiding chemotherapy is the end goal but one thing to look at is tumor tissue and the history of a woman and the treatment she got but it’s quite another thing to use forward-looking studies to try to determine the accuracy,” Lichtenfeld added. Rivera says the new test offers more options to breast cancer patients at low risk who might be hesitant to undergo chemotherapy.
“We are moving toward finding out more about tumors in breast cancers that will help patients make a decision more objectively about next steps,” Rivera said. Vazquez says she doesn’t regret her decision even if at first her family was on the fence. But after finding out she was at low risk post-surgery, she’s thankful there was another medical option.
A new test, called MammaPrint, is making it possible so women could forego chemotherapy. Such was the case for 46-year-old Zaida Vazquez when she was diagnosed with breast cancer this May. Breast cancer is the most commonly diagnosed cancer. Among Hispanic women, breast cancer will be the leading cause of cancer death this year (16 percent), followed by cancers of the lung (13 percent) and colorectum (9 percent), according to the American Cancer Society. Vasquez had surgery in July and then opted for chemotherapy – but stopped midway because she said it made her feel terrible.
Her days were ridden with nausea and exhaustion. That was when her oncologist, Dr. Mayra Rivera, suggested forgoing chemotherapy based on her MammaPrint results that analyzed 70 genes associated with a breast tumor’s chance of metastasizing. “MammaPrint gives me a biology footprint of the tumor,” said Dr. Rivera of Puerto Rico. “And, with patients like Zaida in the early stages of their breast cancer, also known as low risk, this test would benefit more women like her.” MammaPrint is among a growing number of tests attracting interest in the medical world because it lets women know if they could avoid chemotherapy with little risk that they’ll relapse. The tests examine a woman’s genes to determine whether the cancer has a chance of spreading. The tests and MammaPrint gained stature last month when a study exploring its effectiveness was published in The New England Journal of Medicine.
MammaPrint was used in the study, called MINDACT, which analyzed 6,693 breast cancer patients across 112 centers in Europe with newly diagnosed early-stage breast cancer. J. Leonard Lichtenfeld, deputy chief medical officer for the American Cancer Society, said these types of tests are not new. Lichtenfeld said that in the late 90s, there was a substantial amount of tests being developed that looked into the tumor tissue to predict how it would behave over time. Similar to MammaPrint’s approach was Oncotype DX, which took off but only analyzed 21 genes.
MammaPrint looks into the activity of 70 genes. MammaPrint is lesser known and used less often, but has become more popular the past few years. Still, it’s stirred discussion in the medical community because the tests are not 100 percent accurate and could falsely tell a woman she doesn’t need chemotherapy when she actually does. Others, however, believe it will spare thousands of women with early-stage breast cancer the painful – and expensive – experience of going through chemotherapy. The Journal of Medicine article said the MammaPrint clinical trial offers probabilities and not necessarily concrete guidance.
“The reality is that there haven’t been real life trials over an extended period of time to show that these tests work the way they are supposed to work,” Lichtenfeld said. The first author of the MINDACT study said it’s worth noting that this is the first clinical trial of its kind. “There hasn’t been another clinical trial wherein diagnostic tests were evaluated like this, that looked into the biology of the disease, for as long as we did,” said Dr. Laura van ’t Veer, chief research officer of the study. Of the European countries involved in the study, Spain was one of the most active in the trial coming in at about 700 participants.
In centers in Barcelona and Madrid, MammaPrint is already being used frequently. “Everyone can agree that avoiding chemotherapy is the end goal but one thing to look at is tumor tissue and the history of a woman and the treatment she got but it’s quite another thing to use forward-looking studies to try to determine the accuracy,” Lichtenfeld added. Rivera says the new test offers more options to breast cancer patients at low risk who might be hesitant to undergo chemotherapy.
“We are moving toward finding out more about tumors in breast cancers that will help patients make a decision more objectively about next steps,” Rivera said. Vazquez says she doesn’t regret her decision even if at first her family was on the fence. But after finding out she was at low risk post-surgery, she’s thankful there was another medical option.
Labels:
breast cancer,
cancer treatment,
chemotherapy,
mammogram
Location:
Houston, TX, USA
Tuesday, September 13, 2016
400 Students Sing With Cancer-Stricken Teacher Outside His Window
Last Wednesday, 400 students from Christ Presbyterian Academy in Nashville, Tennessee, ditched the pencils and books and got on buses to gather outside a teacher's window.
The students sang songs of worship on the lawn outside the house of Latin and Bible studies teacher Ben Ellis, who is undergoing treatment for an aggressive form of cancer. "The high school principal said, 'Ben has loved us well. Stop what you're doing, load up the buses. We're going to his house to worship with him,'" Nate Morrow, the school's headmaster, told CNN. "He found peace worshiping with others."
Until last week, CNN says, Ellis had been going to work to help him get through radiation treatments and chemotherapy. On Saturday, musician Tim McGraw shared a video on Facebook showing the students singing "Holy Spirit You Are Welcome Here."
The video now has over 20 million views and 390,000 shares.
Labels:
Cancer,
cancer support,
cancer treatment,
students,
teacher
Location:
Houston, TX, USA
Thursday, September 8, 2016
'Cancer Moonshot' Panel: Focus on Immune Therapies
Cancer research should focus on getting more tailored data from individual patients — and provide that information to them and their doctors in a useful way, experts said Wednesday.
And because a new approach called immunotherapy seems to work so spectacularly for some patients, researchers and doctors should create networks to focus on that approach, a panel of cancer experts working on the Obama administration's "cancer moonshot" initiative said in a new report. Immunotherapies include techniques that manipulate the body's own immune defenses against tumor cells, including direct changes to patient's individual cells, drugs that boost immune activity and engineered antibodies trained to recognize particular tumors.
They include the new class of drugs that appear to have made former President Jimmy Carter's melanoma disappear, such as Keytruda and Opdivo, which block the mechanisms that tumors use to hide from immune cells. "Immunotherapy is important. We need to understand it better," said Dr. Douglas Lowy, acting director of the National Cancer Institute. "It is an extremely exciting area of medicine and science today but even now it only benefits a subset of patients," added Tyler Jacks, director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and a panel co-chair. "We must learn why some patients who have melanoma (such as President Carter) or lung cancer respond to checkpoint blockade immunotherapy, whereas patients with many other types of adult cancers, including ovarian, breast, pancreatic, brain, and prostate cancer—as well as most pediatric cancers—have brief responses or do not respond at all," the report reads.
"Current immunotherapy treatments represent only the tip of the iceberg of what is possible," it adds. The report repeats much of what's already been said about the "Cancer Moonshot," spearheaded by Vice President Joe Biden and vulnerable to the funding decisions of a deadlocked and partisan Congress. It focuses on 10 areas that might help the program achieve its goal of making 10 years worth of progress in half that time. There's also a new approach to the old-fashioned bone marrow stem cell transplant. Called chimeric antigen receptor T-cell, or CAR-T, these treatments use a patient's own immune system T-cells, engineered to better recognize cancer cells.
But they require destruction of the patient's existing immune system and that can kill the patient before it cures. One of the main changes proposed by the panel would be to offer tailored tumor profiling to more cancer patients. Right now, patients usually need to be treated at a big cancer center and take part in a major clinical trial to get an individual genetic sequence done. The panel's report proposes offering this service to cancer patients everywhere. "Many patients are eager to provide their data, and gathering this information in a linked network of databases would enable more precise knowledge about what works, in whom, and in which types of cancer," the report reads. And this data could help researchers with a third goal -- creating a big, 3-D atlas of cancer.
It ideally would show how cancer starts in the first place and the mechanisms by which it grows and spreads. Cancer is the No. 2 killer in the U.S. It has replaced heart disease as the No. 1 cause of death in 21 states and it will kill nearly 600,000 people this year, the American Cancer Society says. About 1.68 million Americans will be diagnosed with some form of cancer this year. President Barack Obama launched the "moonshot" initiative in February, asking for close to $1 billion in extra spending over the next two years.
Labels:
Cancer,
cancer research,
cancer treatment
Location:
Houston, TX, USA
Friday, August 12, 2016
Cancer survivors more prone to obesity, especially certain types
Obesity is more common among cancer survivors in the United States than in the general population, a new study finds.
The problem is particularly high among survivors of colorectal and breast cancer, the study authors said.
The researchers analyzed data gathered from nearly 539,000 American adults between 1997 and 2014. Among people with no history of cancer, 21 percent were considered obese in 1997, compared to 29 percent in 2014. Among cancer survivors, the obesity rate went from 22 percent to 32 percent over that time. Colorectal cancer survivors had the largest increases in obesity rates, followed by breast cancer survivors.
The increases were particularly high among blacks who had survived colorectal, breast or prostate cancers, the findings showed. Specifically, for women who had survived colorectal cancer, the largest increases in obesity rates were among those who were young, black and had been diagnosed in the previous two to nine years. Among male colorectal cancer survivors, the largest rate increases were among those who were older, black and had been diagnosed 10 or more years before, the study authors said.
For women who had survived breast cancer, obesity rates increased most among those who were young, white and had been diagnosed within the past year, the study found. For men who had survived prostate cancer, the largest increases in obesity rates were among those who were younger, white and had been diagnosed in the previous two to nine years, according to the report. Principal investigator Heather Greenlee, of Columbia University's Mailman School of Public Health in New York City, said the findings should help focus attention on cancer survivors who face the greatest risk of becoming obese.
"While our findings can be partially explained by the growing population of patients with breast and colorectal cancer -- the two cancers most closely linked to obesity -- we identified additional populations of cancer survivors at risk of obesity not as well understood and which require further study," Greenlee said in a university news release. "These results suggest that obesity is a growing public health burden for cancer survivors, which requires targeted interventions including weight management efforts to stave off the increasing obesity trends we are seeing in cancer survivors," added Greenlee, who is an assistant professor of epidemiology at Columbia.
The researchers analyzed data gathered from nearly 539,000 American adults between 1997 and 2014. Among people with no history of cancer, 21 percent were considered obese in 1997, compared to 29 percent in 2014. Among cancer survivors, the obesity rate went from 22 percent to 32 percent over that time. Colorectal cancer survivors had the largest increases in obesity rates, followed by breast cancer survivors.
The increases were particularly high among blacks who had survived colorectal, breast or prostate cancers, the findings showed. Specifically, for women who had survived colorectal cancer, the largest increases in obesity rates were among those who were young, black and had been diagnosed in the previous two to nine years. Among male colorectal cancer survivors, the largest rate increases were among those who were older, black and had been diagnosed 10 or more years before, the study authors said.
For women who had survived breast cancer, obesity rates increased most among those who were young, white and had been diagnosed within the past year, the study found. For men who had survived prostate cancer, the largest increases in obesity rates were among those who were younger, white and had been diagnosed in the previous two to nine years, according to the report. Principal investigator Heather Greenlee, of Columbia University's Mailman School of Public Health in New York City, said the findings should help focus attention on cancer survivors who face the greatest risk of becoming obese.
"While our findings can be partially explained by the growing population of patients with breast and colorectal cancer -- the two cancers most closely linked to obesity -- we identified additional populations of cancer survivors at risk of obesity not as well understood and which require further study," Greenlee said in a university news release. "These results suggest that obesity is a growing public health burden for cancer survivors, which requires targeted interventions including weight management efforts to stave off the increasing obesity trends we are seeing in cancer survivors," added Greenlee, who is an assistant professor of epidemiology at Columbia.
Labels:
breast cancer,
Cancer,
cancer treatment
Location:
Houston, TX, USA
Subscribe to:
Posts (Atom)















